metformin has been researched along with Prostatic Neoplasms in 196 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial." | 7.80 | Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. ( Bachmann, A; Becker, A; Faison, T; Fajkovic, H; Herman, M; Karakiewicz, PI; Kautzky-Willer, A; Kluth, LA; Lee, RK; Loidl, W; Lotan, Y; Pummer, K; Remzi, M; Rieken, M; Scherr, DS; Schramek, P; Seitz, C; Shariat, SF; Tewari, A; Xylinas, E, 2014) |
| "Bicalutamide 50 mg/day was added after 8 weeks to both arms." | 7.11 | A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). ( Bilusic, M; Dahut, WL; Donahue, RN; Geynisman, DM; Ghatalia, P; Gulley, JL; Karzai, F; Madan, RA; Plimack, ER; Ross, EA; Schlom, J; Toney, NJ; Wroblewski, S; Zibelman, M, 2022) |
| "To investigate the effects of metformin and lifestyle changes on the development of androgen deprivation therapy (ADT)-related metabolic syndrome." | 5.16 | A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. ( Klopper, T; Laing, RW; Langley, SE; Nobes, JP; Russell-Jones, D, 2012) |
| " Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa." | 5.01 | The anticancer potential of metformin on prostate cancer. ( Gandhi, J; Joshi, G; Khan, SA; Smith, NL; Zaidi, S, 2019) |
| " In breast cancer, TGF-β effect on EMT could be potentiated by Fos-related antigen, oncogene HER2, epidermal growth factor, or mitogen-activated protein kinase kinase 5 - extracellular-regulated kinase signaling." | 5.01 | Epithelial mesenchymal transition and resistance in endocrine-related cancers. ( Culig, Z, 2019) |
| "A literature review using PubMed with the keywords: AMPK, androgen deprivation therapy, insulin resistance, metabolic syndrome, metformin and prostate cancer was undertaken." | 4.87 | Metformin in prostate cancer: two for the price of one. ( Ali, SS; Clements, A; Gao, B; Gurney, H; Wong, MKY; Yeap, SHO, 2011) |
| " Questionnaire and linked administrative health data from the Centre for Health Record Linkage and Services Australia were used to identify incident PC, healthcare utilisations, Prostate Specific Antigen (PSA) testing reimbursements and dispensing of metformin and benign prostatic hyperplasia (BPH) prescriptions." | 4.12 | Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study. ( Armstrong, BK; Bang, A; Banks, E; Chiam, K; Egger, S; Nair-Shalliker, V; O'Connell, DL; Patel, MI; Smith, DP; Steinberg, J; Yu, XQ, 2022) |
| "Pre-diagnostic use of metformin and TTh were, independently and jointly, inversely associated with incident prostate and colorectal cancers." | 4.12 | Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men. ( Alzweri, L; Baillargeon, J; Canfield, S; Kristen Peek, M; Kuo, YF; Lopez, DS; Malagaris, I; Milani, SA; Polychronopoulou, E; Tsilidis, KK; Villasante-Tezanos, A, 2022) |
| " The antidiabetic drug metformin has been shown to display antitumoral properties in prostate cancer cell and animal models; however, its role in the formation of metastases remains poorly documented." | 3.81 | Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells. ( Ader, I; Bost, F; Cormont, M; Cuvillier, O; Dirat, B; Golzio, M; Larbret, F; Laurent, K; Lemichez, E; Malavaud, B; Massa, F; Mettouchi, A; Tanti, JF, 2015) |
| "The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial." | 3.80 | Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. ( Bachmann, A; Becker, A; Faison, T; Fajkovic, H; Herman, M; Karakiewicz, PI; Kautzky-Willer, A; Kluth, LA; Lee, RK; Loidl, W; Lotan, Y; Pummer, K; Remzi, M; Rieken, M; Scherr, DS; Schramek, P; Seitz, C; Shariat, SF; Tewari, A; Xylinas, E, 2014) |
| "Metformin, the first-line drug for treating diabetes, selectively kills the chemotherapy resistant subpopulation of cancer stem cells (CSC) in genetically distinct types of breast cancer cell lines." | 3.77 | Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. ( Hirsch, HA; Iliopoulos, D; Struhl, K, 2011) |
| "Lung, prostate, and breast cancer cells were treated with IR (2-8 Gy) after incubation with either ATM or AMPK inhibitors or the AMPK activator metformin." | 3.76 | Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. ( Bristow, RG; Cutz, JC; Harding, S; Liu, C; Rashid, A; Sanli, T; Singh, G; Tsakiridis, T; Wright, J, 2010) |
| "85 g metformin daily for 75 days, urinary retention caused by a prostatic adenoma induced functional renal insufficiency and hyperlactacidemia, rapidly reversed with treatment." | 3.66 | [Reversible lactic acidosis in a diabetic on high dose metformin (author's transl)]. ( Beaudot, C; Brohon, J; Lavieuville, M; Merceron, RE; Noël, M; Raymond, JP, 1980) |
| "Patients with prostate cancer undergoing treatment with radical radiation therapy (RT) plus androgen deprivation therapy (ADT) experience a constellation of deleterious metabolic and anthropometric changes related to hypogonadism that are associated with increased morbidity and mortality." | 3.30 | Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial. ( Ahmed, S; Danielson, B; Dubey, A; Ghosh, S; Hunter, W; Kim, JO; Koul, R; McDonald, M; Ong, AD; Parliament, M; Quon, H; Rowe, L; Sanghera, KP; Sivananthan, G; Usmani, N; Yee, D, 2023) |
| "Bicalutamide 50 mg/day was added after 8 weeks to both arms." | 3.11 | A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). ( Bilusic, M; Dahut, WL; Donahue, RN; Geynisman, DM; Ghatalia, P; Gulley, JL; Karzai, F; Madan, RA; Plimack, ER; Ross, EA; Schlom, J; Toney, NJ; Wroblewski, S; Zibelman, M, 2022) |
| " Metformin added to radiotherapy and ADT did not increase rates of ≥ grade 2 gastrointestinal or genitourinary toxicity and is generally safe and well-tolerated." | 3.01 | Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial. ( Ahmed, S; Danielson, B; Dubey, A; Ghosh, S; Hunter, W; Kim, JO; Koul, R; McDonald, MO; Ong, A; Parliament, M; Quon, H; Rowe, L; Sivananthan, G; Usmani, N; Yee, D, 2021) |
| "A total of 771 men died of prostate cancer during the follow-up." | 3.01 | Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. ( Auvinen, A; Lahtela, J; Murtola, TJ; Raittinen, P; Taari, K; Talala, K; Tammela, TLJ; Vihervuori, VJ, 2021) |
| "Metformin is a safe and low-cost drug." | 3.01 | Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED). ( Alghandour, R; Ebrahim, MA; ELbaiomy, MA; Elshal, AM; Elzaafarany, M; Ghobrial, F, 2021) |
| "Metformin has recently been shown to have potential to reduce prostate cancer risk." | 2.87 | Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort. ( Chow, HS; Cordova, C; Gibson, BA; Hsu, CH; Krouse, RS; Martinez, JA; Nagle, RB; Nguyen, MM; Parnes, HL; Sokoloff, M, 2018) |
| "Metformin is a biguanide oral hypoglycaemic agent commonly used for the treatment of type 2 diabetes mellitus." | 2.84 | Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. ( Cahill, D; Cahill, F; Cathcart, P; Challacombe, B; Chandra, A; Cook, G; Crawley, D; George, G; Gillett, C; Loda, M; Rudman, S; Santa Olalla, A; Van Hemelrijck, M, 2017) |
| "Metformin was generally well tolerated but associated with modest anticancer activity." | 2.84 | Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. ( Acon, P; Baker, C; Galsky, MD; Gimpel-Tetra, K; Holland, J; Jia, R; Leiter, A; Mehrazin, R; Oh, WK; Sablinski, T; Sfakianos, JP; Shaffer, DR; Shahin, M; Tsao, CK, 2017) |
| "In metformin-treated patients, the median duration of usage was 6." | 2.84 | Metformin Does Not Predict for Prostate Cancer Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy. ( Adamovich, E; Bennett, A; Butler, WM; Couture, T; Galbreath, RW; Merrick, GS, 2017) |
| "However, evidence in prostate cancer patients remains mixed owing to an absence of completed randomized trials." | 2.82 | The role of metformin, statins and diet in men on active surveillance for prostate cancer. ( Fleshner, N; Tiwari, R, 2022) |
| "The role of metformin in prostate cancer chemoprevention remains unclear." | 2.80 | Metformin use and risk of prostate cancer: results from the REDUCE study. ( Andriole, GL; Castro-Santamaria, R; Feng, T; Freedland, SJ; Gaines, AR; Howard, LE; Moreira, DM; Sun, X; Vidal, AC, 2015) |
| "Metformin has been demonstrated to reduce cell-viability post-radiotherapy in both rectal and prostate cancer cell lines, with an enhanced effect in tumours with a p53 mutation and increased apoptosis post-radiotherapy for cervical cancer." | 2.72 | Metformin as a radiosensitiser for pelvic malignancy: A systematic review of the literature. ( Clifford, RE; Fok, M; Gerrard, AD; Vimalachandran, D, 2021) |
| "Preventing prostate cancer via dietary supplements should encourage a "first do no harm" or less-is-more approach until future evidence can reverse the concerning trend that more supplementation has resulted in either no impact or an increased risk of prostate cancer." | 2.66 | Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III. ( Moyad, MA, 2020) |
| "The pooled HR of prostate cancer for metformin therapy was 0." | 2.66 | Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies. ( Bi, Y; Chen, T; Liu, X; Sun, Y; Tang, J; Wang, Y; Yan, P; Zhang, ZJ; Zhou, W, 2020) |
| "Prostate cancer is the most common malignant cancer in men worldwide and after lung cancer, it is the second leading cause of cancer mortality in men." | 2.61 | The Relationship Between Prostate Cancer and Metformin Consumption: A Systematic Review and Meta-analysis Study. ( Dehkordi, AH; Ghiasi, B; Motedayen, M; Najafi, F; Sarokhani, D, 2019) |
| "The relationship between metformin and prostate cancer (PCa) remains controversial." | 2.61 | The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis. ( Cui, R; He, K; Hu, H; Wang, H; Ye, S; Yi, L, 2019) |
| "Preventing prostate cancer via dietary supplements should encourage a "first do no harm", or less is more approach until future evidence can reverse the concerning trend that more supplementation has resulted in either no impact or an increased risk of prostate cancer." | 2.58 | Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I. ( Moyad, MA, 2018) |
| "Most prostate cancer patients also have comorbidities that are treated with both prescription and nonprescription medications; furthermore, many use dietary supplements." | 2.55 | Common medications and prostate cancer mortality: a review. ( Greenberg, AJ; Mucci, LA; Stopsack, KH, 2017) |
| "Metformin has numerous antineoplastic effects including an AMP-activated protein kinase-dependent mechanism, AMP-activated protein kinase-independent mechanisms, alteration of insulin and insulin-like growth factor signaling pathways, and suppression of androgen signaling pathways that trigger prostate cancer growth and proliferation." | 2.55 | A review for clinicians: Prostate cancer and the antineoplastic properties of metformin. ( Fam, M; Hankinson, SJ; Patel, NN, 2017) |
| "Metformin use was associated with improved overall survival in studies with clear risk window definition (HR 0." | 2.53 | Metformin and prostate cancer mortality: a meta-analysis. ( Giovannucci, EL; Rider, JR; Stopsack, KH; Ziehr, DR, 2016) |
| "Metformin use was marginally associated with reduction in the risk of biochemical recurrence (pHR: 0." | 2.52 | Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. ( Madhavan, S; Raval, AD; Salkini, M; Sambamoorthi, U; Thakker, D; Vyas, A, 2015) |
| "However, advanced prostate cancer is more difficult to treat and if metastatic, is incurable." | 2.52 | Metformin and prostate cancer stem cells: a novel therapeutic target. ( Klotz, LH; Mayer, MJ; Venkateswaran, V, 2015) |
| "Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer." | 2.52 | Obesity and cancer: mechanistic insights from transdisciplinary studies. ( Allott, EH; Hursting, SD, 2015) |
| "Diabetes mellitus and prostate cancer are 2 of the most important public health concerns, especially in the elderly population." | 2.50 | Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms. ( Hara, N; Hejazi, J; Marotta, F; Rastmanesh, R, 2014) |
| "In 2010, in France, 8,790 men died from prostate cancer despite a low and decreasing mortality rate." | 2.49 | [Pharmaco and diet based prostate cancer prevention]. ( Azzouzi, AR; Cancel-Tassin, G; Cussenot, O; Eisinger, F; Gravis, G; Rossi, D, 2013) |
| "Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors." | 2.49 | Metabolic syndrome as a peculiar target for management of prostate cancer patients. ( Aieta, M; Ardito, R; Bozza, G; Conteduca, V; Di Lorenzo, G, 2013) |
| "Obesity is a known risk factor for many types of cancers and a number of endocrine factors, including adipokines and steroid hormones, are regulated by and regulate AMPK." | 2.49 | Endocrine-related cancers and the role of AMPK. ( Brown, KA; Samarajeewa, NU; Simpson, ER, 2013) |
| "Metformin use was associated with decreased hospital attendances, days of hospitalization, and associated costs, which could help reduce healthcare resource utilization following ADT in the treatment of PCa." | 1.91 | Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study. ( Chan, JSK; Chung, CT; Dee, EC; Hui, JMH; Lee, YHA; Liu, K; Ng, CF; Ng, K; Tse, G, 2023) |
| "The prevalence of prostate cancer according to metformin administration and the risk according to the cumulative duration of metformin were analyzed." | 1.91 | Risk analysis of metformin use in prostate cancer: a national population-based study. ( Heo, Y; Jo, JK; Kim, MJ; Kim, YJ; Song, HK, 2023) |
| "Metformin was found to protect the brain and cerebellum of STZ-induced diabetic rats with Dunning prostate cancer from harm caused by MAT-Lylu metastatic cells." | 1.91 | Oxidative brain and cerebellum injury in diabetes and prostate cancer model: Protective effect of metformin. ( Bulan, OK; Dagsuyu, E; Gul, IB; Koroglu, P; Yanardag, R, 2023) |
| "Metformin treatment failure may be attributed to the high frequency of transcriptional dysregulation, which leads to drug resistance." | 1.91 | Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer. ( Cai, S; Cai, Z; Deng, Y; Feng, Y; Han, Z; He, H; Jia, Z; Li, J; Liang, Y; Liu, R; Lu, J; Xie, J; Ye, J; Zhang, Y; Zhong, W; Zhu, X; Zhuo, Y, 2023) |
| "Metformin users had lower risks of new-onset prostate cancer (hazard ratio, 0." | 1.72 | Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score-Matched Study. ( Chan, JSK; Dee, EC; Hui, JMH; Hui, K; Lee, S; Lee, TTL; Lee, YHA; Liu, T; Liu, X; Ng, K; Tse, G; Wai, AKC; Wong, WT; Zhang, Q; Zhou, J, 2022) |
| "MM10 altered the OCR in prostate cancer cells." | 1.72 | EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells. ( d'Hose, D; Gallez, B; Hardy, M; Jordan, BF; Mathieu, B; Mignion, L; Ouari, O; Sonveaux, P, 2022) |
| "Metformin can enhance the sensitivity of cancer cells to chemotherapy by inducing their metabolic decoupling/imbalance." | 1.72 | Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress. ( Catapano, J; Czyż, J; Kędracka-Krok, S; Luty, M; Madeja, Z; Piwowarczyk, K; Pudełek, M; Siedlar, M; Wróbel, T, 2022) |
| "Metformin was administered for 14 days after diabetes and prostate cancer induced." | 1.72 | Brain Boron Level, DNA Content, and Myeloperoxidase Activity of Metformin-Treated Rats in Diabetes and Prostate Cancer Model. ( Aydın, PK; Bugan, I; Bulan, OK; Dagsuyu, E; Ozel, AB; Yanardag, R; Yarat, A, 2022) |
| "Metformin users were older, more likely non-Caucasian, and had higher body mass index, Gleason score, and number of positive cores." | 1.62 | Association between metformin medication, genetic variation and prostate cancer risk. ( Finelli, A; Fleshner, NE; Freedland, SJ; Hamilton, RJ; Jayalath, VH; Kulkarni, GS; Lee, MJ; Lu, L; van der Kwast, TH; Xu, W, 2021) |
| "Dunning prostate cancer was induced in Copenhagen rats using high metastatic MAT-LyLu cells." | 1.62 | Metformin protects against diabetes-induced heart injury and dunning prostate cancer model. ( Bayrak, BB; Karabulut Bulan, O; Koroglu, P; Yanardag, R, 2021) |
| "Metformin treatment was applied by gavage every day." | 1.62 | Histological and biochemical investigation of the renoprotective effects of metformin in diabetic and prostate cancer model. ( Bayrak, BB; Bugan, I; Karabulut-Bulan, O; Koroglu-Aydın, P; Yanardag, R, 2021) |
| "Metformin ever-use was associated with decreased PC incidence compared with non-diabetics (aHR 0." | 1.62 | Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality. ( Cho, MH; Chun, S; Jeong, SM; Koo, HY; Park, J; Shin, DW, 2021) |
| "2754 prostate cancers were observed versus 3111." | 1.56 | Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients. ( Kincius, M; Linkeviciute-Ulinskiene, D; Patasius, A; Smailyte, G; Zabuliene, L, 2020) |
| "To assess prostate cancer-specific and overall survival in prostate cancer patients with or without preexisting type 2 diabetes mellitus (T2DM) with regards to metformin use." | 1.56 | Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer. ( Kincius, M; Linkeviciute-Ulinskiene, D; Patasius, A; Smailyte, G; Zabuliene, L, 2020) |
| "Metformin, a drug that has been used to treat type 2 diabetes, was found to have antineoplastic activity in different cancers." | 1.56 | Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer. ( Kong, Y; Li, Z; Liu, J; Liu, X; Mao, F; Wang, R; Zhang, Y; Zhang, Z, 2020) |
| "Participants were all prostate cancer-free men aged 40 to 79 years residing in Stockholm County, Sweden, between January 1, 2006, and December 31, 2015." | 1.51 | Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. ( Adolfsson, J; Aly, M; Beckmann, K; Binti Abd Jalal, N; Crawley, D; Eklund, M; Garmo, H; Lantz, A; Nordström, T; Olsson, H; Van Hemelrijck, M, 2019) |
| "Glycemic traits and type 2 diabetes unlikely cause breast and prostate cancer." | 1.51 | Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study. ( Au Yeung, SL; Schooling, CM, 2019) |
| "Treatment with metformin did not result in any apparent improvement in time to BF, time to metastasis detection or OS, but there was a 1." | 1.51 | Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. ( Baldwin, G; Bolton, D; Ischia, J; Patel, O; Ranasinghe, WKB; Sengupta, S; Shulkes, A; Wetherell, D; Williams, S, 2019) |
| "Metformin, a first-line treatment for type 2 diabetes mellitus (T2DM), has recently been recognized for its pleotropic anti-proliferative, anti-cancer, and anti-aging effects." | 1.51 | The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea. ( Hong, Y; Lee, S; Won, S, 2019) |
| "To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa." | 1.48 | Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer. ( Adolfsson, J; Crawley, D; Garmo, H; Holmberg, L; Rudman, S; Stattin, P; Van Hemelrijck, M; Zethelius, B, 2018) |
| "Defining the mechanisms underlying PCa metastasis may lead to insights into how to decrease morbidity and mortality in this disease." | 1.48 | Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control. ( Antognelli, C; Cecchetti, R; Peirce, MJ; Riuzzi, F; Talesa, VN, 2018) |
| " Our findings showed that metformin in combination with quercetin synergistically inhibited the growth, migration and invasion of both PC-3 and LNCaP cells." | 1.48 | Metformin combined with quercetin synergistically repressed prostate cancer cells via inhibition of VEGF/PI3K/Akt signaling pathway. ( Gong, F; Liu, P; Miao, Q; Sun, S, 2018) |
| "Metformin use in veterans with prostate cancer who receive androgen deprivation therapy is associated with improved oncologic outcomes." | 1.48 | Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. ( Abel, EJ; Cryns, VL; Downs, TM; Jarrard, DF; Liou, JI; Richards, KA, 2018) |
| "Metformin use was associated positively with high-aggressive prostate cancer in Blacks (OR 2." | 1.48 | The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. ( Bensen, JT; Cai, J; Drake, BF; Farnan, L; Fontham, ETH; Khan, S; Mohler, JL; Nielsen, ME; Olshan, AF; Troester, MA, 2018) |
| "Metformin is a commonly used drug for the treatment of type II diabetes and atorvastatin is the most prescribed cholesterol-lowering statin." | 1.46 | Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo. ( Du, ZY; Farischon, C; Goodin, S; He, Y; Huang, HR; Kim, S; Li, DL; Wang, ZS; Zhang, K; Zhang, LY; Zheng, X, 2017) |
| "Metformin is a widely studied anti-diabetic drug, which improves glycaemia in patients with type 2 diabetes by targeting this pathway." | 1.46 | Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2. ( Bahl, A; Biernacka, KM; Gillatt, D; Holly, JM; Perks, CM; Persad, RA, 2017) |
| "We propose that metformin represses prostate cancer EMT and metastasis through targeting the COX2/PGE2/STAT3 axis." | 1.46 | Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. ( Jiang, J; Jiang, Y; Lan, W; Liu, G; Liu, Q; Tong, D; Xiao, H; Xu, J; Zhang, D, 2017) |
| "Metformin exposure was defined as a time-dependent variable, stratified first into any use, and into tertiles of cumulative dose." | 1.46 | Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study. ( Chen, CB; Eurich, DT; Johnson, JA; Majumdar, SR, 2017) |
| "Metformin exposure was determined from prescription information from 6 months before the first diagnosis of pancreatic cancer to last follow-up." | 1.46 | Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea. ( Choi, HJ; Choi, JA; Han, CJ; Jang, WI; Jo, AJ; Kang, JK; Kang, SH; Kim, HJ; Kim, MS; Kim, SB; Kim, YJ; Ko, MJ; Paik, EK; Park, CM; Seo, YS; Tchoe, HJ; Yoo, HJ, 2017) |
| "Diabetic men have lowered overall prostate cancer (PCa) risk, while their risk of high-grade disease may be elevated." | 1.46 | Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. ( Auvinen, A; Haring, A; Murtola, TJ; Taari, K; Talala, K; Tammela, TL, 2017) |
| "Metformin was shown to interact with Hh signaling by inhibiting the effector protein glioma-associated oncogene homolog 1 (GLI1) in PCa cells both in vitro and in vivo." | 1.46 | The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells. ( Gonnissen, A; Haustermans, K; Isebaert, S; McKee, CM; Muschel, RJ, 2017) |
| "Metformin has been reported to inhibit the growth of various types of cancers, including prostate cancer." | 1.43 | Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression. ( Chen, X; He, T; Li, C; Lyu, J; Mao, J; Meng, QH, 2016) |
| "Racial/ethnic disparity in prostate cancer is under studied in men with diabetes who are at a higher risk of aggressive prostate cancer." | 1.43 | Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes. ( Downs, JR; Hernandez, J; Kuhn, JG; Lam, YF; Lehman, DM; Lorenzo, C; Mahalingam, D; Ramirez, AG; Stuart, EA; Thompson, IM; Wang, CP; Weitman, S, 2016) |
| "Prostate cancer and type 2 diabetes mellitus (DM2) are both common diseases found in the elderly male population." | 1.43 | Metformin Has a Positive Therapeutic Effect on Prostate Cancer in Patients With Type 2 Diabetes Mellitus. ( Chong, RW; Solomon, SS; Vasudevan, V; Zuber, J, 2016) |
| "Metformin treatment decreased cell growth of PCa cell line 22Rv1 and stalled cells at the G1/S checkpoint in a time- and dose-dependent manner, resulting in increased cells in G1 (P < 0." | 1.43 | Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells. ( Bapat, B; Fleshner, N; Garcia, J; White-Al Habeeb, NM, 2016) |
| "Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer." | 1.43 | Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. ( Adler, A; Clarke, N; Gillessen, S; Gilson, C; James, N; Sydes, MR, 2016) |
| "Metformin users were at significantly higher risk of all-cause mortality." | 1.42 | Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau). ( Beatrice, J; Chun, FF; Grobholz, R; Huber, A; Kwiatkowski, M; Manka, L; Randazzo, M; Recker, F; Wyler, SF, 2015) |
| "A decreased risk of prostate cancer (PCa) has been suggested in men taking aspirin, statins and metformin, although the evidence has been conflicting." | 1.42 | The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. ( Adolfsson, J; Clements, M; Grönberg, H; Karlsson, R; Nordström, T, 2015) |
| "Metformin is a biguanide drug that is widely used for the treatment of type 2 diabetes." | 1.42 | Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. ( Furuya, Y; Kato, H; Koike, H; Miyazawa, Y; Sekine, Y; Suzuki, K, 2015) |
| "Metformin treatment reduced cell viability and enhanced apoptosis for both cell lines and additive effects were observed when LNCaP cells were treated with combined metformin and bicalutamide." | 1.42 | Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor. ( Hasenmayer, D; Jiang, J; Liu, G; Parmar, H; Tong, D; Wang, Y; Yuan, W; Zhang, D, 2015) |
| "Inhibition of prostate cancer progression in HiMyc mice by RAPA was associated with a significant reduction in mTORC1 signaling that was further potentiated by the combination of MET and RAPA." | 1.42 | Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice. ( Blando, J; DiGiovanni, J; Saha, A; Tremmel, L, 2015) |
| "Metformin also has an anti-proliferative effect in preclinical studies of both hematologic malignancies as well as solid cancers and clinical studies testing metformin as an anti-cancer drug are in progress." | 1.42 | Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. ( Bansal, N; Bertino, JR; DiPaola, RS; Mishra, PJ; Stein, M, 2015) |
| "Metformin has received considerable attention as a potential anti-cancer agent." | 1.42 | Metformin effects on biochemical recurrence and metabolic signaling in the prostate. ( Gore, JL; Holt, S; Hu, E; Lin, DW; Morrissey, C; Plymate, S; Porter, MP; Winters, B; Wooldridge, B; Wright, JL; Zeliadt, SB; Zhang, X, 2015) |
| "Metformin has emerged as a potential anticancer agent." | 1.42 | Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells. ( Cai, C; Ge, R; Olumi, AF; Otsetov, AG; Wang, Z; Wu, CL; Wu, S; Zhong, W; Zhuo, Y, 2015) |
| "Metformin use was not associated with a risk reduction in BCR, SP, or ACM." | 1.40 | Effect of metformin on prostate cancer outcomes after radical prostatectomy. ( Bergstralh, EJ; Carlson, RE; Eisenberg, MS; Karnes, RJ; Kaushik, D; Rangel, LJ, 2014) |
| "In the AR(+) LNCaP prostate cancer cells, we found that metformin inhibits androgen-induced CRE activity and IGF-IR gene transcription." | 1.40 | Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. ( Belfiore, A; Maggiolini, M; Malaguarnera, R; Migliaccio, A; Morcavallo, A; Morrione, A; Sacco, A; Squatrito, S, 2014) |
| "Metformin is an approved drug prescribed for diabetes." | 1.40 | Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. ( Demir, U; Klocker, H; Koehler, A; Schneider, R; Schweiger, S, 2014) |
| "Metformin can inhibit the progression of cancer." | 1.40 | Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer. ( Fu, S; Gao, H; Peng, R; Tang, J; Wang, Y; Yao, B; Zhang, L; Zhang, M, 2014) |
| "Metformin exposure was assessed using prescriptions redeemed before the index date." | 1.40 | Metformin use and prostate cancer risk. ( Adami, HO; Batista, JL; Breau, RH; Ehrenstein, V; Mucci, LA; Olumi, AF; Preston, MA; Riis, AH; Sørensen, HT, 2014) |
| "Metformin is an inhibitor of complex 1 in the respiratory chain, and is widely used to reduce insulin resistance." | 1.40 | A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. ( Bowes, B; Downes, MR; Evans, A; Finelli, A; Fleshner, N; Hersey, K; Hofmann, U; Joshua, AM; Koritzinsky, M; Pollak, M; Schwab, M; Sweet, J; Trachtenberg, J; van der Kwast, T; Zannella, VE, 2014) |
| "The cohort consisted of 935 men with prostate cancer and a history of type II diabetes." | 1.40 | The use of metformin in patients with prostate cancer and the risk of death. ( Azoulay, L; Bensimon, L; Pollak, MN; Suissa, S; Yin, H, 2014) |
| "Metformin was found to reduce androgen-dependent cell growth and the expression of AR target genes by inhibiting AR function in prostate cancer cells such as LNCaP and C4-2 cells." | 1.40 | SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells. ( Choi, HS; Jung, C; Lee, K; Lee, SY; Song, CH; Xie, YB, 2014) |
| "Metformin was treated as a time-dependent variable." | 1.40 | Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. ( Tseng, CH, 2014) |
| "Metformin could inhibit TGF-β-induced EMT in Vcap cells, as manifested by inhibition of the increase of N-cadherin (p=0." | 1.40 | Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. ( Han, B; Ma, Q; Qi, M; Shen, C; Wang, L; Xia, P; Yang, M; Zhang, J, 2014) |
| "Prostate cancer is the most commonly diagnosed cancer in males in many populations." | 1.39 | Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. ( Avci, CB; Dodurga, Y; Gunduz, C; Harman, E; Susluer, SY, 2013) |
| "Analyses were focused on breast and prostate cancer to reflect the most common cancers in women and men, respectively." | 1.39 | Breast and prostate cancer survivors in a diabetic cohort: results from the Living with Diabetes Study. ( Doi, SA; Donald, M; Engel, JM; Onitilo, AA; Stankowski, RV; Williams, G, 2013) |
| "Metformin exposure was determined based on prescriptions before cancer diagnosis, and adjusted odds ratios (aOR) were estimated using conditional logistic regression." | 1.39 | Association between metformin use and risk of prostate cancer and its grade. ( Austin, PC; Bell, CM; Fleshner, N; Kulkarni, G; Lipscombe, LL; Margel, D; Urbach, D, 2013) |
| "Metformin use was associated with more recent year of surgery (P<0." | 1.39 | Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. ( Abern, MR; Allott, EH; Amling, CL; Aronson, WJ; Cooperberg, MR; Freedland, SJ; Gerber, L; Kane, CJ; Keto, CJ; Moorman, PG; Terris, MK, 2013) |
| "Metformin treatment significantly improved tumor oxygenation in two xenograft models as measured by IHC, flow cytometry, and PET imaging." | 1.39 | Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. ( Bristow, RG; Chaib, S; Dal Pra, A; Glicksman, R; Koritzinsky, M; McKee, TD; Milosevic, M; Muaddi, H; Stapleton, S; Sykes, J; Wouters, BG; Zamiara, P; Zannella, VE, 2013) |
| "New diagnoses of cancer, including malignant solid tumours and haematological malignancies, occurring during the follow-up were identified from the cohort." | 1.39 | Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. ( Berlin, JA; Demissie, K; Marcella, SW; Qiu, H; Rhoads, GG, 2013) |
| "Metformin use was also independently associated with a decrease in the development of CRPC in patients experiencing biochemical failure compared with diabetic non-metformin patients (odds ratio: 14." | 1.39 | Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. ( Pei, X; Spratt, DE; Zelefsky, MJ; Zhang, C; Zhang, Z; Zumsteg, ZS, 2013) |
| "Metformin was associated with survival benefit both in comparison with other treatments for diabetes and in comparison with a nondiabetic population." | 1.38 | Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. ( Currie, CJ; Gale, EA; Jenkins-Jones, S; Johnson, JA; Morgan, CL; Poole, CD, 2012) |
| "Metformin was associated with a significantly reduced PCa incidence among patients on statins (HR 0." | 1.38 | Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. ( Hernandez, J; Lehman, DM; Lorenzo, C; Wang, CP, 2012) |
| "Cases of prostate cancer were matched up to ten controls on year of birth, date of cohort entry, and duration of follow-up." | 1.37 | Metformin and the incidence of prostate cancer in patients with type 2 diabetes. ( Azoulay, L; Dell'Aniello, S; Gagnon, B; Pollak, M; Suissa, S, 2011) |
| "Records of consecutive prostate cancer patients with coexisting diabetes mellitus type 2 who were treated at the study institution between 15 July 1999 and 31 December 2008 were reviewed." | 1.37 | Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. ( He, XX; Lee, MH; Tu, SM; Yeung, SJ, 2011) |
| "Metformin is a widely prescribed antidiabetic drug associated with a reduced risk of cancer." | 1.37 | Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. ( Auberger, P; Ben Sahra, I; Bost, F; Giorgetti-Peraldi, S; Laurent, K; Le Marchand-Brustel, Y; Regazzetti, C; Robert, G; Tanti, JF, 2011) |
| "Metformin is a commonly used medication for type II diabetes mellitus." | 1.35 | Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. ( Stanford, JL; Wright, JL, 2009) |
| "Metformin is a widely used antidiabetic agent, which regulates glucose homeostasis through inhibition of liver glucose production and an increase in muscle glucose uptake." | 1.35 | The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. ( Auberger, P; Ben Sahra, I; Bost, F; Colosetti, P; Giorgetti-Peraldi, S; Laurent, K; Le Marchand-Brustel, Y; Loubat, A; Tanti, JF, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.02) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (2.04) | 29.6817 |
| 2010's | 143 (72.96) | 24.3611 |
| 2020's | 47 (23.98) | 2.80 |
| Authors | Studies |
|---|---|
| Klose, K | 1 |
| Packeiser, EM | 1 |
| Müller, P | 1 |
| Granados-Soler, JL | 1 |
| Schille, JT | 1 |
| Goericke-Pesch, S | 1 |
| Kietzmann, M | 1 |
| Murua Escobar, H | 1 |
| Nolte, I | 1 |
| Tiwari, R | 1 |
| Fleshner, N | 8 |
| Yao, X | 2 |
| Liu, H | 2 |
| Xu, H | 3 |
| Kim, JO | 2 |
| McDonald, MO | 1 |
| Ong, A | 1 |
| Koul, R | 2 |
| Dubey, A | 2 |
| Hunter, W | 2 |
| Ahmed, S | 2 |
| Quon, H | 2 |
| Yee, D | 2 |
| Parliament, M | 2 |
| Sivananthan, G | 2 |
| Danielson, B | 2 |
| Rowe, L | 2 |
| Ghosh, S | 2 |
| Usmani, N | 3 |
| Khan, S | 3 |
| Chang, SH | 2 |
| Hicks, V | 2 |
| Wang, M | 2 |
| Grubb, RL | 1 |
| Drake, BF | 3 |
| Koroglu Aydın, P | 1 |
| Karabulut-Bulan, O | 2 |
| Bugan, I | 3 |
| Turkyilmaz, IB | 2 |
| Altun, S | 1 |
| Yanardag, R | 6 |
| Freedman, LS | 1 |
| Agay, N | 1 |
| Farmer, R | 1 |
| Murad, H | 1 |
| Olmer, L | 1 |
| Dankner, R | 1 |
| Bilusic, M | 1 |
| Toney, NJ | 1 |
| Donahue, RN | 1 |
| Wroblewski, S | 1 |
| Zibelman, M | 1 |
| Ghatalia, P | 1 |
| Ross, EA | 1 |
| Karzai, F | 1 |
| Madan, RA | 1 |
| Dahut, WL | 1 |
| Gulley, JL | 1 |
| Schlom, J | 1 |
| Plimack, ER | 2 |
| Geynisman, DM | 1 |
| Morgans, AK | 1 |
| Chen, YH | 1 |
| Jarrard, DF | 2 |
| Carducci, M | 1 |
| Liu, G | 3 |
| Eisenberger, M | 1 |
| Bryce, A | 1 |
| Garcia, JA | 1 |
| Dreicer, R | 1 |
| Vogelzang, NJ | 1 |
| Picus, J | 1 |
| Shevrin, D | 1 |
| Hussain, M | 2 |
| DiPaola, RS | 2 |
| Cella, D | 1 |
| Sweeney, CJ | 1 |
| Nair-Shalliker, V | 1 |
| Bang, A | 1 |
| Egger, S | 1 |
| Yu, XQ | 1 |
| Chiam, K | 1 |
| Steinberg, J | 1 |
| Patel, MI | 1 |
| Banks, E | 1 |
| O'Connell, DL | 1 |
| Armstrong, BK | 1 |
| Smith, DP | 1 |
| Lee, YHA | 3 |
| Zhou, J | 1 |
| Hui, JMH | 3 |
| Liu, X | 5 |
| Lee, TTL | 1 |
| Hui, K | 1 |
| Chan, JSK | 3 |
| Wai, AKC | 1 |
| Wong, WT | 1 |
| Liu, T | 1 |
| Ng, K | 3 |
| Lee, S | 2 |
| Dee, EC | 3 |
| Zhang, Q | 3 |
| Tse, G | 3 |
| Lopez, DS | 1 |
| Malagaris, I | 1 |
| Polychronopoulou, E | 1 |
| Tsilidis, KK | 1 |
| Milani, SA | 1 |
| Kristen Peek, M | 1 |
| Villasante-Tezanos, A | 1 |
| Alzweri, L | 1 |
| Baillargeon, J | 1 |
| Kuo, YF | 2 |
| Canfield, S | 1 |
| Sanghera, KP | 1 |
| Ong, AD | 1 |
| McDonald, M | 1 |
| d'Hose, D | 1 |
| Mathieu, B | 1 |
| Mignion, L | 1 |
| Hardy, M | 1 |
| Ouari, O | 1 |
| Jordan, BF | 1 |
| Sonveaux, P | 1 |
| Gallez, B | 1 |
| Olokpa, E | 1 |
| Mandape, SN | 1 |
| Pratap, S | 1 |
| Stewart, MV | 1 |
| Liu, K | 2 |
| Tang, P | 1 |
| Ng, CF | 2 |
| Catapano, J | 3 |
| Luty, M | 3 |
| Wróbel, T | 3 |
| Pudełek, M | 3 |
| Piwowarczyk, K | 3 |
| Kędracka-Krok, S | 3 |
| Siedlar, M | 3 |
| Madeja, Z | 3 |
| Czyż, J | 3 |
| Chung, CT | 1 |
| Jo, JK | 1 |
| Song, HK | 1 |
| Heo, Y | 1 |
| Kim, MJ | 2 |
| Kim, YJ | 3 |
| Seyerle, AA | 1 |
| Mahalingam, D | 2 |
| Hanni, S | 1 |
| Serritella, AV | 1 |
| Fountzilas, C | 1 |
| Michalek, J | 1 |
| Hernandez, B | 1 |
| Sarantopoulos, J | 1 |
| Datta, P | 1 |
| Romero, O | 1 |
| Pillai, SMA | 1 |
| Kuhn, J | 1 |
| Pollak, M | 5 |
| Thompson, IM | 2 |
| Dagsuyu, E | 2 |
| Koroglu, P | 2 |
| Gul, IB | 1 |
| Bulan, OK | 2 |
| Pencik, J | 1 |
| Philippe, C | 1 |
| Schlederer, M | 1 |
| Atas, E | 1 |
| Pecoraro, M | 1 |
| Grund-Gröschke, S | 1 |
| Li, WJ | 1 |
| Tracz, A | 1 |
| Heidegger, I | 1 |
| Lagger, S | 1 |
| Trachtová, K | 1 |
| Oberhuber, M | 1 |
| Heitzer, E | 1 |
| Aksoy, O | 1 |
| Neubauer, HA | 1 |
| Wingelhofer, B | 1 |
| Orlova, A | 1 |
| Witzeneder, N | 1 |
| Dillinger, T | 1 |
| Redl, E | 1 |
| Greiner, G | 1 |
| D'Andrea, D | 1 |
| Östman, JR | 1 |
| Tangermann, S | 1 |
| Hermanova, I | 1 |
| Schäfer, G | 1 |
| Sternberg, F | 1 |
| Pohl, EE | 1 |
| Sternberg, C | 1 |
| Varady, A | 1 |
| Horvath, J | 1 |
| Stoiber, D | 1 |
| Malcolm, TI | 1 |
| Turner, SD | 1 |
| Parkes, EE | 1 |
| Hantusch, B | 1 |
| Egger, G | 1 |
| Rose-John, S | 1 |
| Poli, V | 1 |
| Jain, S | 1 |
| Armstrong, CWD | 1 |
| Hoermann, G | 1 |
| Goffin, V | 1 |
| Aberger, F | 1 |
| Moriggl, R | 1 |
| Carracedo, A | 1 |
| McKinney, C | 1 |
| Kennedy, RD | 1 |
| Klocker, H | 2 |
| Speicher, MR | 1 |
| Tang, DG | 1 |
| Moazzami, AA | 1 |
| Heery, DM | 1 |
| Hacker, M | 1 |
| Kenner, L | 1 |
| Ye, J | 2 |
| Cai, S | 1 |
| Feng, Y | 1 |
| Li, J | 8 |
| Cai, Z | 1 |
| Deng, Y | 1 |
| Liu, R | 1 |
| Zhu, X | 1 |
| Lu, J | 3 |
| Zhuo, Y | 2 |
| Liang, Y | 1 |
| Xie, J | 1 |
| Zhang, Y | 6 |
| He, H | 1 |
| Han, Z | 1 |
| Jia, Z | 1 |
| Zhong, W | 2 |
| Beckmann, K | 1 |
| Crawley, D | 3 |
| Nordström, T | 2 |
| Aly, M | 1 |
| Olsson, H | 1 |
| Lantz, A | 1 |
| Binti Abd Jalal, N | 1 |
| Garmo, H | 3 |
| Adolfsson, J | 3 |
| Eklund, M | 1 |
| Van Hemelrijck, M | 4 |
| Au Yeung, SL | 1 |
| Schooling, CM | 1 |
| Tan, XL | 1 |
| E, JY | 1 |
| Lin, Y | 1 |
| Rebbeck, TR | 1 |
| Lu, SE | 1 |
| Shang, M | 1 |
| Kelly, WK | 1 |
| D'Amico, A | 1 |
| Stein, MN | 1 |
| Zhang, L | 5 |
| Jang, TL | 1 |
| Kim, IY | 1 |
| Demissie, K | 2 |
| Ferrari, A | 1 |
| Lu-Yao, G | 1 |
| Moyad, MA | 2 |
| Kincius, M | 2 |
| Patasius, A | 2 |
| Linkeviciute-Ulinskiene, D | 2 |
| Zabuliene, L | 2 |
| Smailyte, G | 2 |
| Lee, MJ | 2 |
| Jayalath, VH | 1 |
| Xu, W | 1 |
| Lu, L | 1 |
| Freedland, SJ | 4 |
| Fleshner, NE | 4 |
| Kulkarni, GS | 2 |
| Finelli, A | 2 |
| van der Kwast, TH | 1 |
| Hamilton, RJ | 2 |
| Eslami, SS | 1 |
| Jafari, D | 1 |
| Montazeri, H | 1 |
| Sadeghizadeh, M | 1 |
| Tarighi, P | 1 |
| Chen, D | 2 |
| Chou, FJ | 1 |
| Chen, Y | 4 |
| Tian, H | 2 |
| Wang, Y | 8 |
| You, B | 1 |
| Niu, Y | 1 |
| Huang, CP | 1 |
| Yeh, S | 1 |
| Xing, N | 1 |
| Chang, C | 1 |
| Taussky, D | 2 |
| Delouya, G | 2 |
| Bayrak, BB | 3 |
| Karabulut Bulan, O | 1 |
| Raj, GM | 1 |
| Krishnan, R | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 4 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Li, X | 11 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 2 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 2 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 2 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 4 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 2 |
| Zhou, L | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 2 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 2 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 2 |
| Ma, Q | 2 |
| Wang, J | 5 |
| Zhang, E | 1 |
| Zhang, J | 4 |
| Li, Y | 5 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Ren, Y | 1 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 3 |
| Wang, W | 1 |
| Wang, S | 2 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 2 |
| Zhu, J | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Wang, X | 7 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Wu, X | 1 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 2 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 1 |
| Zhang, M | 5 |
| Zhang, H | 1 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 3 |
| Liu, Y | 4 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 2 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 4 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 4 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 5 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 2 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 3 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Li, C | 3 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 2 |
| Wei, H | 1 |
| Wang, Z | 2 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 2 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 3 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 2 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 2 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 2 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 1 |
| Chen, B | 1 |
| Wu, J | 2 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 3 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 2 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 2 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 3 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 2 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Goldberg, H | 1 |
| Mohsin, FK | 1 |
| Berlin, A | 1 |
| Chandrasekar, T | 1 |
| Wallis, CJD | 1 |
| Klaassen, Z | 1 |
| Ahmad, AE | 1 |
| Saskin, R | 1 |
| Kenk, M | 1 |
| Saarela, O | 1 |
| Alibhai, SMH | 1 |
| Kong, Y | 1 |
| Mao, F | 1 |
| Zhang, Z | 4 |
| Wang, R | 1 |
| Liu, J | 1 |
| Ahn, HK | 1 |
| Lee, YH | 1 |
| Koo, KC | 2 |
| Clifford, RE | 1 |
| Gerrard, AD | 1 |
| Fok, M | 1 |
| Vimalachandran, D | 1 |
| Huynh, LM | 1 |
| Keit, E | 1 |
| Huang, E | 1 |
| Carrillo, RC | 1 |
| Ahlering, TE | 1 |
| Boyle, S | 1 |
| Enke, CA | 1 |
| Baine, M | 1 |
| Vihervuori, VJ | 1 |
| Talala, K | 2 |
| Taari, K | 3 |
| Lahtela, J | 1 |
| Tammela, TLJ | 1 |
| Auvinen, A | 3 |
| Raittinen, P | 1 |
| Murtola, TJ | 4 |
| Ozel, AB | 1 |
| Aydın, PK | 1 |
| Yarat, A | 1 |
| Koroglu-Aydın, P | 1 |
| Alghandour, R | 1 |
| Ebrahim, MA | 1 |
| Elshal, AM | 1 |
| Ghobrial, F | 1 |
| Elzaafarany, M | 1 |
| ELbaiomy, MA | 1 |
| Koo, HY | 1 |
| Jeong, SM | 1 |
| Cho, MH | 1 |
| Chun, S | 1 |
| Shin, DW | 1 |
| Park, J | 1 |
| Rudman, S | 2 |
| Stattin, P | 2 |
| Zethelius, B | 2 |
| Holmberg, L | 2 |
| Whitburn, J | 1 |
| Edwards, CM | 1 |
| Sooriakumaran, P | 1 |
| Nguyen, MM | 1 |
| Martinez, JA | 1 |
| Hsu, CH | 1 |
| Sokoloff, M | 1 |
| Krouse, RS | 1 |
| Gibson, BA | 1 |
| Nagle, RB | 1 |
| Parnes, HL | 1 |
| Cordova, C | 1 |
| Chow, HS | 1 |
| Chandra, A | 1 |
| Loda, M | 1 |
| Gillett, C | 1 |
| Cathcart, P | 1 |
| Challacombe, B | 1 |
| Cook, G | 1 |
| Cahill, D | 1 |
| Santa Olalla, A | 1 |
| Cahill, F | 1 |
| George, G | 1 |
| Wang, ZS | 1 |
| Huang, HR | 1 |
| Zhang, LY | 1 |
| Kim, S | 1 |
| Li, DL | 1 |
| Farischon, C | 1 |
| Zhang, K | 1 |
| Zheng, X | 1 |
| Du, ZY | 1 |
| Goodin, S | 1 |
| Chen, CB | 2 |
| Eskin, M | 1 |
| Eurich, DT | 2 |
| Majumdar, SR | 2 |
| Johnson, JA | 3 |
| Park, JS | 1 |
| Lee, KS | 1 |
| Ham, WS | 1 |
| Chung, BH | 1 |
| Antognelli, C | 1 |
| Cecchetti, R | 1 |
| Riuzzi, F | 1 |
| Peirce, MJ | 1 |
| Talesa, VN | 1 |
| Sun, S | 1 |
| Gong, F | 1 |
| Liu, P | 1 |
| Miao, Q | 1 |
| Richards, KA | 1 |
| Liou, JI | 1 |
| Cryns, VL | 1 |
| Downs, TM | 1 |
| Abel, EJ | 1 |
| Tran, LNK | 1 |
| Kichenadasse, G | 1 |
| Sykes, PJ | 1 |
| Eigl, BJ | 1 |
| Cai, J | 1 |
| Nielsen, ME | 1 |
| Troester, MA | 1 |
| Mohler, JL | 1 |
| Fontham, ETH | 1 |
| Farnan, L | 1 |
| Olshan, AF | 1 |
| Bensen, JT | 1 |
| Preisser, F | 1 |
| Karakiewicz, PI | 2 |
| Tilki, D | 1 |
| Lambert, C | 1 |
| Bahary, JP | 1 |
| Wistaff, R | 1 |
| Laskine, M | 1 |
| Nguyen, PV | 1 |
| Durand, M | 1 |
| Saad, F | 1 |
| Aminsharifi, A | 1 |
| Howard, LE | 2 |
| Amling, CL | 2 |
| Aronson, WJ | 2 |
| Cooperberg, MR | 2 |
| Kane, CJ | 2 |
| Terris, MK | 2 |
| Polascik, TJ | 1 |
| Hayashi, T | 1 |
| Fujita, K | 1 |
| Matsushita, M | 1 |
| Hayashi, Y | 1 |
| Uemura, M | 1 |
| Nonomura, N | 1 |
| Zaidi, S | 1 |
| Gandhi, J | 1 |
| Joshi, G | 1 |
| Smith, NL | 1 |
| Khan, SA | 1 |
| Galsky, MD | 2 |
| Shahin, M | 1 |
| Jia, R | 1 |
| Shaffer, DR | 1 |
| Gimpel-Tetra, K | 1 |
| Tsao, CK | 1 |
| Baker, C | 1 |
| Leiter, A | 2 |
| Holland, J | 2 |
| Sablinski, T | 2 |
| Mehrazin, R | 1 |
| Sfakianos, JP | 1 |
| Acon, P | 1 |
| Oh, WK | 2 |
| Ghiasi, B | 1 |
| Sarokhani, D | 1 |
| Najafi, F | 1 |
| Motedayen, M | 1 |
| Dehkordi, AH | 1 |
| He, K | 1 |
| Hu, H | 1 |
| Ye, S | 1 |
| Cui, R | 1 |
| Yi, L | 1 |
| Michalakis, K | 1 |
| Feng, Z | 1 |
| Liu, N | 1 |
| Yan, P | 1 |
| Tang, J | 2 |
| Chen, T | 1 |
| Zhou, W | 1 |
| Bi, Y | 1 |
| Zhang, ZJ | 1 |
| Kuo, YJ | 1 |
| Sung, FC | 1 |
| Hsieh, PF | 1 |
| Chang, HP | 1 |
| Wu, KL | 1 |
| Wu, HC | 1 |
| Ranasinghe, WKB | 1 |
| Williams, S | 1 |
| Ischia, J | 1 |
| Wetherell, D | 1 |
| Baldwin, G | 1 |
| Shulkes, A | 1 |
| Sengupta, S | 1 |
| Bolton, D | 1 |
| Patel, O | 1 |
| Culig, Z | 1 |
| Raffaele, M | 1 |
| Pittalà, V | 1 |
| Zingales, V | 1 |
| Barbagallo, I | 1 |
| Salerno, L | 1 |
| Li Volti, G | 1 |
| Romeo, G | 1 |
| Carota, G | 1 |
| Sorrenti, V | 1 |
| Vanella, L | 1 |
| Hong, Y | 1 |
| Won, S | 1 |
| Moiseeva, O | 1 |
| Deschênes-Simard, X | 1 |
| St-Germain, E | 1 |
| Igelmann, S | 1 |
| Huot, G | 1 |
| Cadar, AE | 1 |
| Bourdeau, V | 1 |
| Pollak, MN | 4 |
| Ferbeyre, G | 1 |
| Spratt, DE | 2 |
| Zelefsky, MJ | 2 |
| Bensimon, L | 2 |
| Suissa, S | 3 |
| Azoulay, L | 3 |
| Avci, CB | 1 |
| Harman, E | 1 |
| Dodurga, Y | 1 |
| Susluer, SY | 1 |
| Gunduz, C | 1 |
| Onitilo, AA | 1 |
| Donald, M | 1 |
| Stankowski, RV | 1 |
| Engel, JM | 1 |
| Williams, G | 1 |
| Doi, SA | 2 |
| Fendt, SM | 1 |
| Bell, EL | 1 |
| Keibler, MA | 1 |
| Davidson, SM | 1 |
| Wirth, GJ | 1 |
| Fiske, B | 1 |
| Mayers, JR | 1 |
| Schwab, M | 2 |
| Bellinger, G | 1 |
| Csibi, A | 1 |
| Patnaik, A | 1 |
| Blouin, MJ | 1 |
| Cantley, LC | 1 |
| Guarente, L | 1 |
| Blenis, J | 1 |
| Olumi, AF | 3 |
| Vander Heiden, MG | 1 |
| Stephanopoulos, G | 1 |
| Eisinger, F | 1 |
| Cancel-Tassin, G | 1 |
| Azzouzi, AR | 1 |
| Gravis, G | 1 |
| Rossi, D | 1 |
| Cussenot, O | 1 |
| Conteduca, V | 1 |
| Di Lorenzo, G | 1 |
| Bozza, G | 1 |
| Ardito, R | 1 |
| Aieta, M | 1 |
| Kaushik, D | 1 |
| Karnes, RJ | 1 |
| Eisenberg, MS | 1 |
| Rangel, LJ | 1 |
| Carlson, RE | 1 |
| Bergstralh, EJ | 1 |
| Margel, D | 4 |
| Urbach, D | 2 |
| Lipscombe, LL | 2 |
| Bell, CM | 2 |
| Kulkarni, G | 2 |
| Austin, PC | 3 |
| Urbach, DR | 1 |
| Penney, KL | 2 |
| Stampfer, MJ | 2 |
| Rieken, M | 2 |
| Kluth, LA | 1 |
| Xylinas, E | 1 |
| Fajkovic, H | 1 |
| Becker, A | 1 |
| Herman, M | 1 |
| Lotan, Y | 1 |
| Seitz, C | 1 |
| Schramek, P | 1 |
| Remzi, M | 1 |
| Loidl, W | 1 |
| Pummer, K | 1 |
| Lee, RK | 1 |
| Faison, T | 1 |
| Scherr, DS | 1 |
| Kautzky-Willer, A | 1 |
| Bachmann, A | 1 |
| Tewari, A | 1 |
| Shariat, SF | 2 |
| Allott, EH | 2 |
| Abern, MR | 1 |
| Gerber, L | 1 |
| Keto, CJ | 1 |
| Moorman, PG | 1 |
| Shen, M | 1 |
| Ratnam, M | 1 |
| Dou, QP | 1 |
| Akinyeke, T | 1 |
| Matsumura, S | 1 |
| Schalfer, ED | 1 |
| Saxena, A | 1 |
| Logan, SK | 1 |
| Zannella, VE | 2 |
| Dal Pra, A | 1 |
| Muaddi, H | 1 |
| McKee, TD | 1 |
| Stapleton, S | 1 |
| Sykes, J | 1 |
| Glicksman, R | 1 |
| Chaib, S | 1 |
| Zamiara, P | 1 |
| Milosevic, M | 1 |
| Wouters, BG | 1 |
| Bristow, RG | 2 |
| Koritzinsky, M | 2 |
| Zanders, MM | 1 |
| Vissers, PA | 1 |
| van de Poll-Franse, LV | 1 |
| Malaguarnera, R | 1 |
| Sacco, A | 1 |
| Morcavallo, A | 1 |
| Squatrito, S | 1 |
| Migliaccio, A | 1 |
| Morrione, A | 1 |
| Maggiolini, M | 1 |
| Belfiore, A | 1 |
| Demir, U | 1 |
| Koehler, A | 1 |
| Schneider, R | 1 |
| Schweiger, S | 1 |
| Azvolinsky, A | 1 |
| Rastmanesh, R | 1 |
| Hejazi, J | 1 |
| Marotta, F | 1 |
| Hara, N | 1 |
| Yao, B | 1 |
| Fu, S | 1 |
| Gao, H | 1 |
| Peng, R | 1 |
| Fan, J | 1 |
| Guan, Z | 1 |
| Li, L | 1 |
| Hsieh, JT | 1 |
| He, D | 1 |
| Guo, P | 1 |
| Preston, MA | 2 |
| Riis, AH | 1 |
| Ehrenstein, V | 1 |
| Breau, RH | 2 |
| Batista, JL | 1 |
| Mucci, LA | 2 |
| Adami, HO | 2 |
| Sørensen, HT | 2 |
| Joshua, AM | 1 |
| Downes, MR | 1 |
| Bowes, B | 1 |
| Hersey, K | 1 |
| Hofmann, U | 1 |
| Evans, A | 1 |
| van der Kwast, T | 1 |
| Trachtenberg, J | 1 |
| Sweet, J | 1 |
| Clyne, M | 1 |
| Weckermann, D | 1 |
| Yin, H | 1 |
| Mitrakas, AG | 1 |
| Kalamida, D | 1 |
| Koukourakis, MI | 1 |
| Batista, J | 1 |
| Hu, MB | 1 |
| Bai, PD | 1 |
| Zhu, WH | 1 |
| Ding, Q | 2 |
| Jiang, HW | 1 |
| Lee, SY | 1 |
| Song, CH | 1 |
| Xie, YB | 1 |
| Jung, C | 1 |
| Choi, HS | 1 |
| Lee, K | 1 |
| Tseng, CH | 1 |
| Shen, C | 1 |
| Xia, P | 1 |
| Qi, M | 1 |
| Yang, M | 1 |
| Han, B | 1 |
| Diefenbach, M | 1 |
| Foster, M | 1 |
| Greenberg, A | 1 |
| Taneja, SS | 1 |
| Randazzo, M | 1 |
| Beatrice, J | 1 |
| Huber, A | 1 |
| Grobholz, R | 1 |
| Manka, L | 1 |
| Wyler, SF | 1 |
| Chun, FF | 1 |
| Recker, F | 1 |
| Kwiatkowski, M | 1 |
| Danzig, MR | 1 |
| Kotamarti, S | 1 |
| Ghandour, RA | 1 |
| Rothberg, MB | 1 |
| Dubow, BP | 1 |
| Benson, MC | 1 |
| Badani, KK | 1 |
| McKiernan, JM | 2 |
| Shao, C | 1 |
| Ahmad, N | 1 |
| Hodges, K | 1 |
| Ratliff, T | 1 |
| Dirat, B | 1 |
| Ader, I | 1 |
| Golzio, M | 1 |
| Massa, F | 1 |
| Mettouchi, A | 1 |
| Laurent, K | 5 |
| Larbret, F | 2 |
| Malavaud, B | 1 |
| Cormont, M | 2 |
| Lemichez, E | 1 |
| Cuvillier, O | 1 |
| Tanti, JF | 6 |
| Bost, F | 6 |
| Yu, H | 1 |
| Yin, L | 1 |
| Gao, X | 1 |
| Merrick, GS | 1 |
| Bennett, A | 1 |
| Couture, T | 1 |
| Butler, WM | 1 |
| Galbreath, RW | 1 |
| Adamovich, E | 1 |
| Rees, J | 1 |
| Raval, AD | 2 |
| Thakker, D | 1 |
| Vyas, A | 1 |
| Salkini, M | 1 |
| Madhavan, S | 2 |
| Sambamoorthi, U | 2 |
| Hwang, IC | 1 |
| Park, SM | 1 |
| Shin, D | 1 |
| Ahn, HY | 1 |
| Deng, D | 1 |
| Skrip, L | 1 |
| Clements, M | 1 |
| Karlsson, R | 1 |
| Grönberg, H | 1 |
| Wahlfors, T | 1 |
| Haring, A | 2 |
| Stenman, UH | 1 |
| Tammela, TL | 3 |
| Schleutker, J | 1 |
| Kato, H | 1 |
| Sekine, Y | 1 |
| Furuya, Y | 1 |
| Miyazawa, Y | 1 |
| Koike, H | 1 |
| Suzuki, K | 1 |
| Tong, D | 2 |
| Parmar, H | 1 |
| Hasenmayer, D | 1 |
| Yuan, W | 1 |
| Li, HX | 1 |
| Gao, JM | 1 |
| Liang, JQ | 1 |
| Xi, JM | 1 |
| Fu, M | 1 |
| Wu, YJ | 1 |
| Saha, A | 1 |
| Blando, J | 1 |
| Tremmel, L | 1 |
| DiGiovanni, J | 1 |
| O'Brien, AJ | 1 |
| Villani, LA | 1 |
| Broadfield, LA | 1 |
| Houde, VP | 1 |
| Galic, S | 1 |
| Blandino, G | 1 |
| Kemp, BE | 1 |
| Tsakiridis, T | 2 |
| Muti, P | 1 |
| Steinberg, GR | 1 |
| Loubière, C | 1 |
| Goiran, T | 1 |
| Djabari, Z | 1 |
| Bansal, N | 1 |
| Mishra, PJ | 1 |
| Stein, M | 1 |
| Bertino, JR | 1 |
| Kowall, B | 1 |
| Stang, A | 1 |
| Rathmann, W | 1 |
| Kostev, K | 1 |
| Giannoni, E | 1 |
| Taddei, ML | 1 |
| Morandi, A | 1 |
| Comito, G | 1 |
| Calvani, M | 1 |
| Bianchini, F | 1 |
| Richichi, B | 1 |
| Raugei, G | 1 |
| Wong, N | 1 |
| Tang, D | 1 |
| Chiarugi, P | 1 |
| Winters, B | 1 |
| Plymate, S | 1 |
| Zeliadt, SB | 1 |
| Holt, S | 1 |
| Hu, E | 1 |
| Lin, DW | 1 |
| Morrissey, C | 1 |
| Wooldridge, B | 1 |
| Gore, JL | 1 |
| Porter, MP | 1 |
| Wright, JL | 2 |
| Mayer, MJ | 1 |
| Klotz, LH | 2 |
| Venkateswaran, V | 3 |
| Feng, T | 1 |
| Vidal, AC | 1 |
| Gaines, AR | 1 |
| Moreira, DM | 1 |
| Castro-Santamaria, R | 1 |
| Andriole, GL | 1 |
| Ge, R | 1 |
| Wu, S | 1 |
| Otsetov, AG | 1 |
| Cai, C | 1 |
| Wu, CL | 1 |
| Hursting, SD | 1 |
| Tsutsumi, Y | 1 |
| Nomiyama, T | 1 |
| Kawanami, T | 1 |
| Hamaguchi, Y | 1 |
| Terawaki, Y | 1 |
| Tanaka, T | 1 |
| Murase, K | 1 |
| Motonaga, R | 1 |
| Tanabe, M | 1 |
| Yanase, T | 1 |
| Stopsack, KH | 2 |
| Ziehr, DR | 1 |
| Rider, JR | 1 |
| Giovannucci, EL | 1 |
| Sayyid, RK | 2 |
| He, T | 1 |
| Mao, J | 1 |
| Lyu, J | 1 |
| Meng, QH | 1 |
| Wang, CP | 2 |
| Lehman, DM | 2 |
| Lam, YF | 1 |
| Kuhn, JG | 1 |
| Weitman, S | 1 |
| Lorenzo, C | 2 |
| Downs, JR | 1 |
| Stuart, EA | 1 |
| Hernandez, J | 2 |
| Ramirez, AG | 1 |
| Chong, RW | 1 |
| Vasudevan, V | 1 |
| Zuber, J | 1 |
| Solomon, SS | 1 |
| Roberts, MJ | 1 |
| Yaxley, JW | 1 |
| Coughlin, GD | 1 |
| Gianduzzo, TR | 1 |
| Esler, RC | 1 |
| Dunglison, NT | 1 |
| Chambers, SK | 1 |
| Medcraft, RJ | 1 |
| Chow, CW | 1 |
| Schirra, HJ | 1 |
| Richards, RS | 1 |
| Kienzle, N | 1 |
| Lu, M | 1 |
| Brereton, I | 1 |
| Samaratunga, H | 1 |
| Perry-Keene, J | 1 |
| Payton, D | 1 |
| Oyama, C | 1 |
| Lavin, MF | 1 |
| Gardiner, RA | 1 |
| White-Al Habeeb, NM | 1 |
| Garcia, J | 1 |
| Bapat, B | 1 |
| Uchio, E | 1 |
| Meyskens, FL | 1 |
| Wang, PH | 1 |
| Gillessen, S | 1 |
| Gilson, C | 1 |
| James, N | 1 |
| Adler, A | 1 |
| Sydes, MR | 1 |
| Clarke, N | 1 |
| Greenberg, AJ | 1 |
| Joentausta, RM | 1 |
| Kujala, PM | 1 |
| Visakorpi, T | 1 |
| Mattes, MD | 1 |
| Pan, X | 1 |
| Wei, W | 1 |
| Zhu, W | 1 |
| Ma, J | 1 |
| Xue, W | 1 |
| Gu, B | 1 |
| Sheng, L | 1 |
| Sun, F | 1 |
| Gong, J | 1 |
| Qiu, W | 1 |
| Jiang, H | 1 |
| Galdieri, L | 1 |
| Gatla, H | 1 |
| Vancurova, I | 1 |
| Vancura, A | 1 |
| Biernacka, KM | 1 |
| Persad, RA | 1 |
| Bahl, A | 1 |
| Gillatt, D | 1 |
| Holly, JM | 1 |
| Perks, CM | 1 |
| Häggström, C | 1 |
| Robinson, D | 1 |
| Grundmark, B | 1 |
| Gudbjörnsdottir, S | 1 |
| Zaorsky, NG | 1 |
| Shaikh, T | 1 |
| Ruth, K | 1 |
| Sharda, P | 1 |
| Hayes, SB | 1 |
| Sobczak, ML | 1 |
| Hallman, MA | 1 |
| Smaldone, MC | 1 |
| Chen, DY | 1 |
| Horwitz, EM | 1 |
| Hankinson, SJ | 1 |
| Fam, M | 1 |
| Patel, NN | 1 |
| Xu, J | 1 |
| Lan, W | 1 |
| Xiao, H | 1 |
| Jang, WI | 1 |
| Kim, MS | 1 |
| Kang, SH | 1 |
| Jo, AJ | 1 |
| Tchoe, HJ | 1 |
| Park, CM | 1 |
| Kim, HJ | 1 |
| Choi, JA | 1 |
| Choi, HJ | 1 |
| Paik, EK | 1 |
| Seo, YS | 1 |
| Yoo, HJ | 1 |
| Kang, JK | 1 |
| Han, CJ | 1 |
| Kim, SB | 1 |
| Ko, MJ | 1 |
| Gonnissen, A | 1 |
| Isebaert, S | 1 |
| McKee, CM | 1 |
| Muschel, RJ | 1 |
| Haustermans, K | 1 |
| Cohen, P | 1 |
| Zakikhani, M | 1 |
| Dowling, RJ | 1 |
| Sonenberg, N | 1 |
| Stanford, JL | 1 |
| Ben Sahra, I | 4 |
| Giuliano, S | 1 |
| Ponzio, G | 1 |
| Gounon, P | 1 |
| Le Marchand-Brustel, Y | 3 |
| Giorgetti-Peraldi, S | 3 |
| Bertolotto, C | 1 |
| Deckert, M | 1 |
| Auberger, P | 3 |
| Hou, M | 1 |
| Venier, N | 1 |
| Sugar, L | 1 |
| Musquera, M | 1 |
| Kiss, A | 2 |
| Klotz, L | 1 |
| Sanli, T | 1 |
| Rashid, A | 1 |
| Harding, S | 1 |
| Cutz, JC | 1 |
| Singh, G | 1 |
| Wright, J | 1 |
| Patel, T | 1 |
| Hruby, G | 1 |
| Badani, K | 1 |
| Abate-Shen, C | 1 |
| Dell'Aniello, S | 1 |
| Gagnon, B | 1 |
| Alfarouk, KO | 1 |
| Bashir, AH | 1 |
| Iliopoulos, D | 1 |
| Hirsch, HA | 1 |
| Struhl, K | 1 |
| He, XX | 1 |
| Tu, SM | 1 |
| Lee, MH | 1 |
| Yeung, SJ | 1 |
| Clements, A | 1 |
| Gao, B | 1 |
| Yeap, SHO | 1 |
| Wong, MKY | 1 |
| Ali, SS | 1 |
| Gurney, H | 1 |
| Balink, H | 1 |
| Hemmelder, MH | 1 |
| de Graaf, W | 1 |
| Grond, J | 1 |
| Regazzetti, C | 1 |
| Robert, G | 1 |
| Nobes, JP | 1 |
| Langley, SE | 1 |
| Klopper, T | 1 |
| Russell-Jones, D | 1 |
| Laing, RW | 1 |
| Monteagudo, S | 1 |
| Pérez-Martínez, FC | 1 |
| Pérez-Carrión, MD | 1 |
| Guerra, J | 1 |
| Merino, S | 1 |
| Sánchez-Verdú, MP | 1 |
| Ceña, V | 1 |
| Currie, CJ | 1 |
| Poole, CD | 1 |
| Jenkins-Jones, S | 1 |
| Gale, EA | 1 |
| Morgan, CL | 1 |
| Hitron, A | 1 |
| Adams, V | 1 |
| Talbert, J | 1 |
| Steinke, D | 1 |
| Colquhoun, AJ | 1 |
| Venier, NA | 1 |
| Vandersluis, AD | 1 |
| Besla, R | 1 |
| Sugar, LM | 1 |
| Brower, V | 1 |
| Brown, KA | 1 |
| Samarajeewa, NU | 1 |
| Simpson, ER | 1 |
| Qiu, H | 1 |
| Rhoads, GG | 1 |
| Berlin, JA | 1 |
| Marcella, SW | 1 |
| Zhang, C | 1 |
| Zumsteg, ZS | 1 |
| Pei, X | 1 |
| Loubat, A | 1 |
| Colosetti, P | 1 |
| Beaudot, C | 1 |
| Merceron, RE | 1 |
| Lavieuville, M | 1 |
| Noël, M | 1 |
| Brohon, J | 1 |
| Raymond, JP | 1 |
| Gormsen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1)[NCT02614859] | Phase 2 | 29 participants (Actual) | Interventional | 2015-12-01 | Completed | ||
| Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort[NCT01433913] | Phase 2 | 20 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| M-RePoRT: Metformin - Rising PSA Remote Trial[NCT02376166] | 15 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| Mansmed Trial : Repurposing Metformin as Anticancer Drug, RCT in Advanced Prostate Cancer[NCT03137186] | Phase 2 | 120 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with undetectable PSA after 32 weeks (NCT02614859)
Timeframe: 32 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bicalutamide | 3 |
| Metformin and Bicalutamide | 5 |
Number of patients with BMI decline after 32 weeks (NCT02614859)
Timeframe: 32 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A | 4 |
| Arm B | 12 |
Median PSA decline after 8 weeks % (range) (NCT02614859)
Timeframe: 8 weeks
| Intervention | percent change (Median) |
|---|---|
| Bicalutamide | NA |
| Metformin and Bicalutamide | 9 |
Number of patients with PSA decline after 8 weeks (observation vs metformin) (NCT02614859)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bicalutamide | 1 |
| Metformin and Bicalutamide | 8 |
Number of patients with PSA decline ≥ 85% after 32 weeks (NCT02614859)
Timeframe: 32 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A | 6 |
| Arm B | 10 |
Average number of positively stained cells that exhibited nuclear fragmentation from five randomly selected high-power fields (40x) in the tumor region was calculated for each participant (NCT01433913)
Timeframe: 12 weeks
| Intervention | Number of positive cells (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | 0.07 |
| Arm II (Placebo) | 0.1 |
(NCT01433913)
Timeframe: 12 weeks
| Intervention | % positive cells (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | 37.5 |
| Arm II (Placebo) | 13.3 |
Data between the two study groups will be compared using a two-group t-test at a two-sided 0.05 level of significance. If the data are not normally distributed, a non-parametric rank-sum test will be utilized. (NCT01433913)
Timeframe: 12 weeks
| Intervention | % positively stained nuclei (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | 6.5 |
| Arm II (Placebo) | 3.67 |
(NCT01433913)
Timeframe: Baseline and 12 weeks
| Intervention | % change (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | -11.42 |
| Arm II (Placebo) | 5.66 |
(NCT01433913)
Timeframe: Baseline and 12 weeks
| Intervention | % change (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | 7.07 |
| Arm II (Placebo) | -2.24 |
(NCT01433913)
Timeframe: Baseline and 12 weeks
| Intervention | % change (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | -6.53 |
| Arm II (Placebo) | 5.98 |
(NCT01433913)
Timeframe: Baseline and 12 weeks
| Intervention | % change (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | 0.48 |
| Arm II (Placebo) | -6.49 |
(NCT01433913)
Timeframe: Baseline and 12 weeks
| Intervention | % change (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | -16.12 |
| Arm II (Placebo) | 2.04 |
(NCT01433913)
Timeframe: 12 weeks
| Intervention | % positive cells (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | 66.7 |
| Arm II (Placebo) | 63.3 |
(NCT01433913)
Timeframe: 12 weeks
| Intervention | ug/g tissue (Median) |
|---|---|
| Arm I (Metformin Hydrochloride) | 5.71 |
| Arm II (Placebo) | 0 |
Feasibility will be defined as completion of all telemedicine visits by > 2/3 of enrolled patients (unless treatment discontinued early for toxicity or disease progression). (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin | 12 |
Percent of patients with 6-month PSA stable 20% change at 6 months as compared to baseline (NCT02376166)
Timeframe: baseline and 6 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin | 7 |
Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 4th reported outcome - Number of episodes of bloating (NCT02376166)
Timeframe: 6 months
| Intervention | episodes (Number) | ||||
|---|---|---|---|---|---|
| No problem | Very small problem | Small problem | Moderate problem | Big problem | |
| Metformin | 8 | 1 | 1 | 0 | 0 |
Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 3rd reported outcome - Number of episodes of flatulence (NCT02376166)
Timeframe: 6 months
| Intervention | episodes (Number) | ||||
|---|---|---|---|---|---|
| No problem | Very small problem | Small problem | Moderate problem | Big problem | |
| Metformin | 8 | 1 | 1 | 0 | 0 |
Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 5th reported outcome - Number of episodes of nausea (NCT02376166)
Timeframe: 6 months
| Intervention | episodes (Number) | ||||
|---|---|---|---|---|---|
| No problem | Very small problem | Small problem | Moderate problem | Big problem | |
| Metformin | 8 | 1 | 0 | 1 | 0 |
Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 6th reported outcome - Number of episodes of vomiting (NCT02376166)
Timeframe: 6 months
| Intervention | episodes (Number) | ||||
|---|---|---|---|---|---|
| No problem | Very small problem | Small problem | Moderate problem | Big problem | |
| Metformin | 10 | 0 | 0 | 0 | 0 |
Quality of LIfe as measured by a modified RAND 36-Item Health Survey. 2st reported outcome - Number of episodes of watery bowel movements (NCT02376166)
Timeframe: 6 months
| Intervention | episodes (Number) | ||||
|---|---|---|---|---|---|
| No problem | Very small problem | Small problem | Moderate problem | Big problem | |
| Metformin | 4 | 3 | 2 | 1 | 0 |
Quality of LIfe as measured by a modified RAND 36-Item Health Survey. Ist reported outcome - Number of episodes of Increased frequency of bowel movements (NCT02376166)
Timeframe: 6 months
| Intervention | episodes (Number) | ||||
|---|---|---|---|---|---|
| No problem | Very small problem | Small problem | Moderate problem | Big problem | |
| Metformin | 6 | 3 | 0 | 1 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - I would participate in a clinical trial in the future." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 10 | 3 | 0 | 0 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - I would recommend participation in a telemedicine clinical trial to other patients." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 11 | 2 | 0 | 0 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - I would participate in a clinical trial where the entire trial was conducted remotely without requiring any visits to the study center." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 8 | 3 | 1 | 0 | 1 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - I felt that I was able to communicate well with the study team, even though most contact was through the tablet computer video instead of in person." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 12 | 1 | 0 | 0 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - I would participate in a telemedicine clinical trial in the future." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 9 | 4 | 0 | 0 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - The time commitment required for participation in this trial was not overly burdensome." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 11 | 2 | 0 | 0 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - Participation in this trial did not disrupt my work or other activities." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 11 | 2 | 0 | 0 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - I found it easy to use the telemonitoring tablet computer." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 5 | 2 | 0 | 4 | 2 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - This telemedicine approach eases the travel burden for participation in clinical trials for patients." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 10 | 3 | 0 | 0 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - This telemedicine approach eases the financial burden of participation in clinical trials for patients." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 11 | 2 | 0 | 0 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - My local physician was adequately informed about my participation in this trial (if applicable)." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 11 | 2 | 0 | 0 | 0 |
"Patient satisfaction with the remote clinical trial experience as measured by a patient satisfaction survey - I felt I was monitored sufficiently closely while enrolled in this trial." (NCT02376166)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | |
| Metformin | 11 | 2 | 0 | 0 | 0 |
Quality of LIfe as measured by a modified RAND 36-Item Health Survey. Ist reported outcome - Number of episodes of urgency to have a bowel movement (NCT02376166)
Timeframe: 6 months
| Intervention | episodes (Number) | ||||
|---|---|---|---|---|---|
| No problem | Very small problem | Small problem | Moderate problem | Big problem | |
| Metformin | 4 | 4 | 1 | 1 | 0 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
34 reviews available for metformin and Prostatic Neoplasms
| Article | Year |
|---|---|
The role of metformin, statins and diet in men on active surveillance for prostate cancer.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Prostatic Neoplasms; Second | 2022 |
The role of metformin, statins and diet in men on active surveillance for prostate cancer.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Prostatic Neoplasms; Second | 2022 |
The role of metformin, statins and diet in men on active surveillance for prostate cancer.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Prostatic Neoplasms; Second | 2022 |
The Impact of Metformin Use with Survival Outcomes in Urologic Cancers: A Systematic Review and Meta-Analysis.
Topics: China; Humans; Hypoglycemic Agents; Kidney Neoplasms; Male; Metformin; Prognosis; Prostatic Neoplasm | 2021 |
The Impact of Metformin Use with Survival Outcomes in Urologic Cancers: A Systematic Review and Meta-Analysis.
Topics: China; Humans; Hypoglycemic Agents; Kidney Neoplasms; Male; Metformin; Prognosis; Prostatic Neoplasm | 2021 |
The Impact of Metformin Use with Survival Outcomes in Urologic Cancers: A Systematic Review and Meta-Analysis.
Topics: China; Humans; Hypoglycemic Agents; Kidney Neoplasms; Male; Metformin; Prognosis; Prostatic Neoplasm | 2021 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III.
Topics: Adult; Aspirin; Cardiovascular Diseases; Child; Diet; Dietary Supplements; Humans; Hydroxymethylglut | 2020 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III.
Topics: Adult; Aspirin; Cardiovascular Diseases; Child; Diet; Dietary Supplements; Humans; Hydroxymethylglut | 2020 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III.
Topics: Adult; Aspirin; Cardiovascular Diseases; Child; Diet; Dietary Supplements; Humans; Hydroxymethylglut | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review.
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2020 |
Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review.
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2020 |
Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review.
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2020 |
Metformin as a radiosensitiser for pelvic malignancy: A systematic review of the literature.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Female; Humans; Hypoglycemic Agents; Male; Metformin; Ne | 2021 |
Metformin as a radiosensitiser for pelvic malignancy: A systematic review of the literature.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Female; Humans; Hypoglycemic Agents; Male; Metformin; Ne | 2021 |
Metformin as a radiosensitiser for pelvic malignancy: A systematic review of the literature.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Female; Humans; Hypoglycemic Agents; Male; Metformin; Ne | 2021 |
Metformin and Prostate Cancer: a New Role for an Old Drug.
Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Male; Metabolic Syndrome; Metformin; Prostatic | 2017 |
Metformin and Prostate Cancer: a New Role for an Old Drug.
Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Male; Metabolic Syndrome; Metformin; Prostatic | 2017 |
Metformin and Prostate Cancer: a New Role for an Old Drug.
Topics: Androgen Antagonists; Antineoplastic Agents; Humans; Male; Metabolic Syndrome; Metformin; Prostatic | 2017 |
Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.
Topics: Asian People; Diabetes Mellitus, Type 2; Ethnicity; Humans; Male; Metformin; Prostatic Neoplasms; Ri | 2018 |
Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.
Topics: Asian People; Diabetes Mellitus, Type 2; Ethnicity; Humans; Male; Metformin; Prostatic Neoplasms; Ri | 2018 |
Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.
Topics: Asian People; Diabetes Mellitus, Type 2; Ethnicity; Humans; Male; Metformin; Prostatic Neoplasms; Ri | 2018 |
Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.
Topics: Animals; Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; | 2019 |
Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.
Topics: Animals; Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; | 2019 |
Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.
Topics: Animals; Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; | 2019 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I.
Topics: Aspirin; Cardiovascular Diseases; Diet; Dietary Supplements; Humans; Hydroxymethylglutaryl-CoA Reduc | 2018 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I.
Topics: Aspirin; Cardiovascular Diseases; Diet; Dietary Supplements; Humans; Hydroxymethylglutaryl-CoA Reduc | 2018 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I.
Topics: Aspirin; Cardiovascular Diseases; Diet; Dietary Supplements; Humans; Hydroxymethylglutaryl-CoA Reduc | 2018 |
The anticancer potential of metformin on prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Clinical T | 2019 |
The anticancer potential of metformin on prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Clinical T | 2019 |
The anticancer potential of metformin on prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Clinical T | 2019 |
The Relationship Between Prostate Cancer and Metformin Consumption: A Systematic Review and Meta-analysis Study.
Topics: Humans; Male; Metformin; Prostatic Neoplasms | 2019 |
The Relationship Between Prostate Cancer and Metformin Consumption: A Systematic Review and Meta-analysis Study.
Topics: Humans; Male; Metformin; Prostatic Neoplasms | 2019 |
The Relationship Between Prostate Cancer and Metformin Consumption: A Systematic Review and Meta-analysis Study.
Topics: Humans; Male; Metformin; Prostatic Neoplasms | 2019 |
The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis.
Topics: Disease Susceptibility; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Prognosis; Proporti | 2019 |
The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis.
Topics: Disease Susceptibility; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Prognosis; Proporti | 2019 |
The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis.
Topics: Disease Susceptibility; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Prognosis; Proporti | 2019 |
Metformin use and prostate cancer risk: A meta-analysis of cohort studies.
Topics: Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; | 2019 |
Metformin use and prostate cancer risk: A meta-analysis of cohort studies.
Topics: Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; | 2019 |
Metformin use and prostate cancer risk: A meta-analysis of cohort studies.
Topics: Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; | 2019 |
Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.
Topics: Alcoholism; Case-Control Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Gly | 2020 |
Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.
Topics: Alcoholism; Case-Control Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Gly | 2020 |
Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.
Topics: Alcoholism; Case-Control Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Gly | 2020 |
Epithelial mesenchymal transition and resistance in endocrine-related cancers.
Topics: Benzopyrans; Breast Neoplasms; Cadherins; Cell Plasticity; Cytokines; Disease Progression; Epidermal | 2019 |
Epithelial mesenchymal transition and resistance in endocrine-related cancers.
Topics: Benzopyrans; Breast Neoplasms; Cadherins; Cell Plasticity; Cytokines; Disease Progression; Epidermal | 2019 |
Epithelial mesenchymal transition and resistance in endocrine-related cancers.
Topics: Benzopyrans; Breast Neoplasms; Cadherins; Cell Plasticity; Cytokines; Disease Progression; Epidermal | 2019 |
[Pharmaco and diet based prostate cancer prevention].
Topics: 5-alpha Reductase Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Diet | 2013 |
[Pharmaco and diet based prostate cancer prevention].
Topics: 5-alpha Reductase Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Diet | 2013 |
[Pharmaco and diet based prostate cancer prevention].
Topics: 5-alpha Reductase Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Diet | 2013 |
Metabolic syndrome as a peculiar target for management of prostate cancer patients.
Topics: Body Composition; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Gro | 2013 |
Metabolic syndrome as a peculiar target for management of prostate cancer patients.
Topics: Body Composition; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Gro | 2013 |
Metabolic syndrome as a peculiar target for management of prostate cancer patients.
Topics: Body Composition; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Gro | 2013 |
Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms.
Topics: Carcinogenesis; Diabetes Mellitus, Type 2; Diet Therapy; Genetic Predisposition to Disease; Humans; | 2014 |
Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms.
Topics: Carcinogenesis; Diabetes Mellitus, Type 2; Diet Therapy; Genetic Predisposition to Disease; Humans; | 2014 |
Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms.
Topics: Carcinogenesis; Diabetes Mellitus, Type 2; Diet Therapy; Genetic Predisposition to Disease; Humans; | 2014 |
Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Disease-Free Survival; Drug Synergism; Human | 2015 |
Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Disease-Free Survival; Drug Synergism; Human | 2015 |
Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Disease-Free Survival; Drug Synergism; Human | 2015 |
Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies.
Topics: Humans; Male; Metformin; Neoplasm Recurrence, Local; Prostatic Neoplasms; Publication Bias; Risk Fac | 2014 |
Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies.
Topics: Humans; Male; Metformin; Neoplasm Recurrence, Local; Prostatic Neoplasms; Publication Bias; Risk Fac | 2014 |
Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies.
Topics: Humans; Male; Metformin; Neoplasm Recurrence, Local; Prostatic Neoplasms; Publication Bias; Risk Fac | 2014 |
Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Neoplasm Staging; Orchiect | 2015 |
Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Neoplasm Staging; Orchiect | 2015 |
Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Neoplasm Staging; Orchiect | 2015 |
Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasm Recurrence, Local; | 2015 |
Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasm Recurrence, Local; | 2015 |
Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasm Recurrence, Local; | 2015 |
Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis.
Topics: Aged; Anticarcinogenic Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Med | 2015 |
Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis.
Topics: Aged; Anticarcinogenic Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Med | 2015 |
Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis.
Topics: Aged; Anticarcinogenic Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Med | 2015 |
Metformin and prostate cancer stem cells: a novel therapeutic target.
Topics: Antineoplastic Agents; Biomarkers; Drug Resistance, Neoplasm; Humans; Male; Metformin; Mitochondria; | 2015 |
Metformin and prostate cancer stem cells: a novel therapeutic target.
Topics: Antineoplastic Agents; Biomarkers; Drug Resistance, Neoplasm; Humans; Male; Metformin; Mitochondria; | 2015 |
Metformin and prostate cancer stem cells: a novel therapeutic target.
Topics: Antineoplastic Agents; Biomarkers; Drug Resistance, Neoplasm; Humans; Male; Metformin; Mitochondria; | 2015 |
Obesity and cancer: mechanistic insights from transdisciplinary studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Caloric R | 2015 |
Obesity and cancer: mechanistic insights from transdisciplinary studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Caloric R | 2015 |
Obesity and cancer: mechanistic insights from transdisciplinary studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Caloric R | 2015 |
Metformin and prostate cancer mortality: a meta-analysis.
Topics: Diabetes Mellitus; Humans; Male; Metformin; Prostatic Neoplasms; Retrospective Studies; Risk | 2016 |
Metformin and prostate cancer mortality: a meta-analysis.
Topics: Diabetes Mellitus; Humans; Male; Metformin; Prostatic Neoplasms; Retrospective Studies; Risk | 2016 |
Metformin and prostate cancer mortality: a meta-analysis.
Topics: Diabetes Mellitus; Humans; Male; Metformin; Prostatic Neoplasms; Retrospective Studies; Risk | 2016 |
Diabetes Mellitus Type 2: A Driving Force for Urological Complications.
Topics: Animals; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Prostatic Neopla | 2016 |
Diabetes Mellitus Type 2: A Driving Force for Urological Complications.
Topics: Animals; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Prostatic Neopla | 2016 |
Diabetes Mellitus Type 2: A Driving Force for Urological Complications.
Topics: Animals; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Prostatic Neopla | 2016 |
Potential role for metformin in urologic oncology.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mal | 2016 |
Potential role for metformin in urologic oncology.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mal | 2016 |
Potential role for metformin in urologic oncology.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mal | 2016 |
Common medications and prostate cancer mortality: a review.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dietary Supplements; Humans; Hydroxy | 2017 |
Common medications and prostate cancer mortality: a review.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dietary Supplements; Humans; Hydroxy | 2017 |
Common medications and prostate cancer mortality: a review.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dietary Supplements; Humans; Hydroxy | 2017 |
A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
Topics: AMP-Activated Protein Kinases; Androgens; Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; | 2017 |
A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
Topics: AMP-Activated Protein Kinases; Androgens; Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; | 2017 |
A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
Topics: AMP-Activated Protein Kinases; Androgens; Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; | 2017 |
Metformin in prostate cancer: two for the price of one.
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syn | 2011 |
Metformin in prostate cancer: two for the price of one.
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syn | 2011 |
Metformin in prostate cancer: two for the price of one.
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syn | 2011 |
The influence of antidiabetic medications on the development and progression of prostate cancer.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Age | 2012 |
The influence of antidiabetic medications on the development and progression of prostate cancer.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Age | 2012 |
The influence of antidiabetic medications on the development and progression of prostate cancer.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Age | 2012 |
Endocrine-related cancers and the role of AMPK.
Topics: AMP-Activated Protein Kinases; Biological Factors; Cell Transformation, Neoplastic; Colonic Neoplasm | 2013 |
Endocrine-related cancers and the role of AMPK.
Topics: AMP-Activated Protein Kinases; Biological Factors; Cell Transformation, Neoplastic; Colonic Neoplasm | 2013 |
Endocrine-related cancers and the role of AMPK.
Topics: AMP-Activated Protein Kinases; Biological Factors; Cell Transformation, Neoplastic; Colonic Neoplasm | 2013 |
17 trials available for metformin and Prostatic Neoplasms
| Article | Year |
|---|---|
Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Gastrointestinal Diseases; Humans; Hypoglycemic Agents | 2021 |
Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Gastrointestinal Diseases; Humans; Hypoglycemic Agents | 2021 |
Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Gastrointestinal Diseases; Humans; Hypoglycemic Agents | 2021 |
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).
Topics: Androgen Antagonists; Anilides; Humans; Male; Metformin; Nitriles; Obesity; Overweight; Programmed C | 2022 |
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).
Topics: Androgen Antagonists; Anilides; Humans; Male; Metformin; Nitriles; Obesity; Overweight; Programmed C | 2022 |
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).
Topics: Androgen Antagonists; Anilides; Humans; Male; Metformin; Nitriles; Obesity; Overweight; Programmed C | 2022 |
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Hormones; Hum | 2022 |
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Hormones; Hum | 2022 |
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Hormones; Hum | 2022 |
Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
Topics: Androgen Antagonists; Androgens; Cholesterol; Humans; Male; Metformin; Prostatic Neoplasms | 2023 |
Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
Topics: Androgen Antagonists; Androgens; Cholesterol; Humans; Male; Metformin; Prostatic Neoplasms | 2023 |
Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
Topics: Androgen Antagonists; Androgens; Cholesterol; Humans; Male; Metformin; Prostatic Neoplasms | 2023 |
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Humans; Insulins; Male; Metabolic Syndrome; Metformin; Prosta | 2023 |
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Humans; Insulins; Male; Metabolic Syndrome; Metformin; Prosta | 2023 |
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Humans; Insulins; Male; Metabolic Syndrome; Metformin; Prosta | 2023 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Finland; Glycemic Control; Humans; Hypoglycemic Agen | 2021 |
Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Finland; Glycemic Control; Humans; Hypoglycemic Agen | 2021 |
Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Finland; Glycemic Control; Humans; Hypoglycemic Agen | 2021 |
Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED).
Topics: Aged; Aged, 80 and over; Humans; Male; Metformin; Middle Aged; Prostatic Neoplasms | 2021 |
Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED).
Topics: Aged; Aged, 80 and over; Humans; Male; Metformin; Middle Aged; Prostatic Neoplasms | 2021 |
Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED).
Topics: Aged; Aged, 80 and over; Humans; Male; Metformin; Middle Aged; Prostatic Neoplasms | 2021 |
Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Delayed-Action Preparations; Double-Blind Method; Hu | 2018 |
Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Delayed-Action Preparations; Double-Blind Method; Hu | 2018 |
Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Delayed-Action Preparations; Double-Blind Method; Hu | 2018 |
Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
Topics: Antineoplastic Agents; Double-Blind Method; Humans; Hypoglycemic Agents; Longevity; Male; Metformin; | 2017 |
Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
Topics: Antineoplastic Agents; Double-Blind Method; Humans; Hypoglycemic Agents; Longevity; Male; Metformin; | 2017 |
Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
Topics: Antineoplastic Agents; Double-Blind Method; Humans; Hypoglycemic Agents; Longevity; Male; Metformin; | 2017 |
Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer.
Topics: Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor; Combined Modality Therapy; Humans; Male; Met | 2017 |
Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer.
Topics: Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor; Combined Modality Therapy; Humans; Male; Met | 2017 |
Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer.
Topics: Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor; Combined Modality Therapy; Humans; Male; Met | 2017 |
Will metformin postpone high-fat diet promotion of TRAMP mouse prostate cancer development and progression?
Topics: Animals; Biomarkers, Tumor; Blood Glucose; Diet, High-Fat; Disease Progression; Insulin; Insulin-Lik | 2014 |
Will metformin postpone high-fat diet promotion of TRAMP mouse prostate cancer development and progression?
Topics: Animals; Biomarkers, Tumor; Blood Glucose; Diet, High-Fat; Disease Progression; Insulin; Insulin-Lik | 2014 |
Will metformin postpone high-fat diet promotion of TRAMP mouse prostate cancer development and progression?
Topics: Animals; Biomarkers, Tumor; Blood Glucose; Diet, High-Fat; Disease Progression; Insulin; Insulin-Lik | 2014 |
Metformin Does Not Predict for Prostate Cancer Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy.
Topics: Aged; Diabetes Mellitus; Humans; Hypoglycemic Agents; Image-Guided Biopsy; Male; Metformin; Neoplasm | 2017 |
Metformin Does Not Predict for Prostate Cancer Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy.
Topics: Aged; Diabetes Mellitus; Humans; Hypoglycemic Agents; Image-Guided Biopsy; Male; Metformin; Neoplasm | 2017 |
Metformin Does Not Predict for Prostate Cancer Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy.
Topics: Aged; Diabetes Mellitus; Humans; Hypoglycemic Agents; Image-Guided Biopsy; Male; Metformin; Neoplasm | 2017 |
Metformin use and risk of prostate cancer: results from the REDUCE study.
Topics: Aged; Biopsy; Diabetes Mellitus; Double-Blind Method; Humans; Hypoglycemic Agents; Male; Metformin; | 2015 |
Metformin use and risk of prostate cancer: results from the REDUCE study.
Topics: Aged; Biopsy; Diabetes Mellitus; Double-Blind Method; Humans; Hypoglycemic Agents; Male; Metformin; | 2015 |
Metformin use and risk of prostate cancer: results from the REDUCE study.
Topics: Aged; Biopsy; Diabetes Mellitus; Double-Blind Method; Humans; Hypoglycemic Agents; Male; Metformin; | 2015 |
Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.
Topics: Antigens, Neoplasm; Atorvastatin; Biomarkers, Tumor; Citric Acid; Double-Blind Method; Drug Therapy, | 2016 |
Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.
Topics: Antigens, Neoplasm; Atorvastatin; Biomarkers, Tumor; Citric Acid; Double-Blind Method; Drug Therapy, | 2016 |
Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.
Topics: Antigens, Neoplasm; Atorvastatin; Biomarkers, Tumor; Citric Acid; Double-Blind Method; Drug Therapy, | 2016 |
An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Go | 2017 |
An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Go | 2017 |
An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Go | 2017 |
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Behavior Therapy; Blood Glucose; Disease-Free Surviva | 2012 |
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Behavior Therapy; Blood Glucose; Disease-Free Surviva | 2012 |
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Behavior Therapy; Blood Glucose; Disease-Free Surviva | 2012 |
146 other studies available for metformin and Prostatic Neoplasms
| Article | Year |
|---|---|
Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
Topics: Animals; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dichl | 2021 |
Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
Topics: Animals; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dichl | 2021 |
Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
Topics: Animals; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dichl | 2021 |
Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer.
Topics: Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Proportiona | 2022 |
Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer.
Topics: Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Proportiona | 2022 |
Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer.
Topics: Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Proportiona | 2022 |
The protective effect of metformin against testicular damage in diabetes and prostate cancer model.
Topics: Animals; Diabetes Mellitus, Experimental; Humans; Male; Metformin; Oxidative Stress; Prostate; Prost | 2022 |
The protective effect of metformin against testicular damage in diabetes and prostate cancer model.
Topics: Animals; Diabetes Mellitus, Experimental; Humans; Male; Metformin; Oxidative Stress; Prostate; Prost | 2022 |
The protective effect of metformin against testicular damage in diabetes and prostate cancer model.
Topics: Animals; Diabetes Mellitus, Experimental; Humans; Male; Metformin; Oxidative Stress; Prostate; Prost | 2022 |
Metformin Treatment Among Men With Diabetes and the Risk of Prostate Cancer: A Population-Based Historical Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agen | 2022 |
Metformin Treatment Among Men With Diabetes and the Risk of Prostate Cancer: A Population-Based Historical Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agen | 2022 |
Metformin Treatment Among Men With Diabetes and the Risk of Prostate Cancer: A Population-Based Historical Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agen | 2022 |
Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
Topics: Diabetes Mellitus; Humans; Male; Metformin; Obesity; Prospective Studies; Prostatic Hyperplasia; Pro | 2022 |
Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
Topics: Diabetes Mellitus; Humans; Male; Metformin; Obesity; Prospective Studies; Prostatic Hyperplasia; Pro | 2022 |
Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
Topics: Diabetes Mellitus; Humans; Male; Metformin; Obesity; Prospective Studies; Prostatic Hyperplasia; Pro | 2022 |
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score-Matched Study.
Topics: Aged; Androgen Antagonists; Androgens; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Propensit | 2022 |
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score-Matched Study.
Topics: Aged; Androgen Antagonists; Androgens; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Propensit | 2022 |
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score-Matched Study.
Topics: Aged; Androgen Antagonists; Androgens; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Propensit | 2022 |
Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men.
Topics: Aged; Breast Neoplasms, Male; Colorectal Neoplasms; Humans; Male; Medicare; Metformin; Prostate; Pro | 2022 |
Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men.
Topics: Aged; Breast Neoplasms, Male; Colorectal Neoplasms; Humans; Male; Medicare; Metformin; Prostate; Pro | 2022 |
Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men.
Topics: Aged; Breast Neoplasms, Male; Colorectal Neoplasms; Humans; Male; Medicare; Metformin; Prostate; Pro | 2022 |
EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells.
Topics: Antioxidants; Carbon; Cell Line, Tumor; Glutathione Disulfide; Humans; Male; Metformin; Mitochondria | 2022 |
EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells.
Topics: Antioxidants; Carbon; Cell Line, Tumor; Glutathione Disulfide; Humans; Male; Metformin; Mitochondria | 2022 |
EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells.
Topics: Antioxidants; Carbon; Cell Line, Tumor; Glutathione Disulfide; Humans; Male; Metformin; Mitochondria | 2022 |
Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells.
Topics: Androgens; Castration; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose; Humans; In | 2022 |
Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells.
Topics: Androgens; Castration; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose; Humans; In | 2022 |
Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells.
Topics: Androgens; Castration; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose; Humans; In | 2022 |
Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Diabetes Mellitus; Humans; Male; Metformin | 2023 |
Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Diabetes Mellitus; Humans; Male; Metformin | 2023 |
Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Diabetes Mellitus; Humans; Male; Metformin | 2023 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Hu | 2022 |
Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study.
Topics: Androgen Antagonists; Androgens; Cohort Studies; Diabetes Mellitus; Hospitals; Humans; Male; Metform | 2023 |
Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study.
Topics: Androgen Antagonists; Androgens; Cohort Studies; Diabetes Mellitus; Hospitals; Humans; Male; Metform | 2023 |
Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study.
Topics: Androgen Antagonists; Androgens; Cohort Studies; Diabetes Mellitus; Hospitals; Humans; Male; Metform | 2023 |
Risk analysis of metformin use in prostate cancer: a national population-based study.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms; Retros | 2023 |
Risk analysis of metformin use in prostate cancer: a national population-based study.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms; Retros | 2023 |
Risk analysis of metformin use in prostate cancer: a national population-based study.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms; Retros | 2023 |
Post-diagnostic metformin and statin use and risk of biochemical recurrence in Veterans diagnosed with prostate cancer.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Neoplasm Recurrence, Local; | 2023 |
Post-diagnostic metformin and statin use and risk of biochemical recurrence in Veterans diagnosed with prostate cancer.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Neoplasm Recurrence, Local; | 2023 |
Post-diagnostic metformin and statin use and risk of biochemical recurrence in Veterans diagnosed with prostate cancer.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Neoplasm Recurrence, Local; | 2023 |
Oxidative brain and cerebellum injury in diabetes and prostate cancer model: Protective effect of metformin.
Topics: Acetylcholinesterase; Animals; Antioxidants; Brain; Cerebellum; Diabetes Mellitus, Experimental; Glu | 2023 |
Oxidative brain and cerebellum injury in diabetes and prostate cancer model: Protective effect of metformin.
Topics: Acetylcholinesterase; Animals; Antioxidants; Brain; Cerebellum; Diabetes Mellitus, Experimental; Glu | 2023 |
Oxidative brain and cerebellum injury in diabetes and prostate cancer model: Protective effect of metformin.
Topics: Acetylcholinesterase; Animals; Antioxidants; Brain; Cerebellum; Diabetes Mellitus, Experimental; Glu | 2023 |
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Humans; Male; Mechanistic Target | 2023 |
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Humans; Male; Mechanistic Target | 2023 |
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Humans; Male; Mechanistic Target | 2023 |
Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer.
Topics: Cell Cycle; Cell Line, Tumor; Humans; Male; Metformin; Prostatic Neoplasms; Transcription Factors | 2023 |
Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer.
Topics: Cell Cycle; Cell Line, Tumor; Humans; Male; Metformin; Prostatic Neoplasms; Transcription Factors | 2023 |
Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer.
Topics: Cell Cycle; Cell Line, Tumor; Humans; Male; Metformin; Prostatic Neoplasms; Transcription Factors | 2023 |
Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Topics: Adult; Aged; Biopsy; Case-Control Studies; Cohort Studies; Diabetes Mellitus; Educational Status; Ge | 2019 |
Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Topics: Adult; Aged; Biopsy; Case-Control Studies; Cohort Studies; Diabetes Mellitus; Educational Status; Ge | 2019 |
Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Topics: Adult; Aged; Biopsy; Case-Control Studies; Cohort Studies; Diabetes Mellitus; Educational Status; Ge | 2019 |
Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Ethnic | 2019 |
Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Ethnic | 2019 |
Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Ethnic | 2019 |
Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethyl | 2020 |
Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethyl | 2020 |
Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethyl | 2020 |
Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Prostatic Neopla | 2020 |
Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Prostatic Neopla | 2020 |
Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Prostatic Neopla | 2020 |
Association between metformin medication, genetic variation and prostate cancer risk.
Topics: Aged; Biopsy; Case-Control Studies; DNA, Neoplasm; Genetic Predisposition to Disease; Genome-Wide As | 2021 |
Association between metformin medication, genetic variation and prostate cancer risk.
Topics: Aged; Biopsy; Case-Control Studies; DNA, Neoplasm; Genetic Predisposition to Disease; Genome-Wide As | 2021 |
Association between metformin medication, genetic variation and prostate cancer risk.
Topics: Aged; Biopsy; Case-Control Studies; DNA, Neoplasm; Genetic Predisposition to Disease; Genome-Wide As | 2021 |
Combination of Curcumin and Metformin Inhibits Cell Growth and Induces Apoptosis without Affecting the Cell Cycle in LNCaP Prostate Cancer Cell Line.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Curcumin; Humans; Male; Metformin; Pros | 2021 |
Combination of Curcumin and Metformin Inhibits Cell Growth and Induces Apoptosis without Affecting the Cell Cycle in LNCaP Prostate Cancer Cell Line.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Curcumin; Humans; Male; Metformin; Pros | 2021 |
Combination of Curcumin and Metformin Inhibits Cell Growth and Induces Apoptosis without Affecting the Cell Cycle in LNCaP Prostate Cancer Cell Line.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Curcumin; Humans; Male; Metformin; Pros | 2021 |
Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2020 |
Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2020 |
Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2020 |
Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity.
Topics: Animals; Cell Line, Tumor; Humans; Male; Metformin; Mice; MicroRNAs; Neoplasm Transplantation; PC-3 | 2020 |
Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity.
Topics: Animals; Cell Line, Tumor; Humans; Male; Metformin; Mice; MicroRNAs; Neoplasm Transplantation; PC-3 | 2020 |
Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity.
Topics: Animals; Cell Line, Tumor; Humans; Male; Metformin; Mice; MicroRNAs; Neoplasm Transplantation; PC-3 | 2020 |
Impact of diabetes and metformin use on prostate cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2020 |
Impact of diabetes and metformin use on prostate cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2020 |
Impact of diabetes and metformin use on prostate cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2020 |
Metformin protects against diabetes-induced heart injury and dunning prostate cancer model.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Diabetes M | 2021 |
Metformin protects against diabetes-induced heart injury and dunning prostate cancer model.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Diabetes M | 2021 |
Metformin protects against diabetes-induced heart injury and dunning prostate cancer model.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Diabetes M | 2021 |
Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorizations, do they matter?
Topics: Genetic Variation; Genotype; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2021 |
Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorizations, do they matter?
Topics: Genetic Variation; Genotype; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2021 |
Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorizations, do they matter?
Topics: Genetic Variation; Genotype; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2021 |
The suggested chemopreventive association of metformin with prostate cancer in diabetic patients.
Topics: Aged; Aged, 80 and over; Chemoprevention; Cohort Studies; Diabetes Complications; Humans; Hypoglycem | 2021 |
The suggested chemopreventive association of metformin with prostate cancer in diabetic patients.
Topics: Aged; Aged, 80 and over; Chemoprevention; Cohort Studies; Diabetes Complications; Humans; Hypoglycem | 2021 |
The suggested chemopreventive association of metformin with prostate cancer in diabetic patients.
Topics: Aged; Aged, 80 and over; Chemoprevention; Cohort Studies; Diabetes Complications; Humans; Hypoglycem | 2021 |
Response to the Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorization, do they matter?
Topics: Genetic Variation; Genotype; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2021 |
Response to the Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorization, do they matter?
Topics: Genetic Variation; Genotype; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2021 |
Response to the Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorization, do they matter?
Topics: Genetic Variation; Genotype; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2021 |
Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Synerg | 2020 |
Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Synerg | 2020 |
Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Synerg | 2020 |
Protective Effects of Metformin Against Biochemical Failure Following Radical Prostatectomy or Radiation Therapy in Localized Prostate Cancer.
Topics: Aged; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoplasm Grading | 2021 |
Protective Effects of Metformin Against Biochemical Failure Following Radical Prostatectomy or Radiation Therapy in Localized Prostate Cancer.
Topics: Aged; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoplasm Grading | 2021 |
Protective Effects of Metformin Against Biochemical Failure Following Radical Prostatectomy or Radiation Therapy in Localized Prostate Cancer.
Topics: Aged; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoplasm Grading | 2021 |
Brain Boron Level, DNA Content, and Myeloperoxidase Activity of Metformin-Treated Rats in Diabetes and Prostate Cancer Model.
Topics: Animals; Boron; Brain; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Male; Metformin | 2022 |
Brain Boron Level, DNA Content, and Myeloperoxidase Activity of Metformin-Treated Rats in Diabetes and Prostate Cancer Model.
Topics: Animals; Boron; Brain; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Male; Metformin | 2022 |
Brain Boron Level, DNA Content, and Myeloperoxidase Activity of Metformin-Treated Rats in Diabetes and Prostate Cancer Model.
Topics: Animals; Boron; Brain; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Male; Metformin | 2022 |
Histological and biochemical investigation of the renoprotective effects of metformin in diabetic and prostate cancer model.
Topics: Animals; Antioxidants; Catalase; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Kidney; Lipid | 2021 |
Histological and biochemical investigation of the renoprotective effects of metformin in diabetic and prostate cancer model.
Topics: Animals; Antioxidants; Catalase; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Kidney; Lipid | 2021 |
Histological and biochemical investigation of the renoprotective effects of metformin in diabetic and prostate cancer model.
Topics: Animals; Antioxidants; Catalase; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Kidney; Lipid | 2021 |
Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Health Surveys; Humans; Hydroxymethylglutar | 2021 |
Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Health Surveys; Humans; Hydroxymethylglutar | 2021 |
Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Health Surveys; Humans; Hydroxymethylglutar | 2021 |
Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypertension | 2018 |
Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypertension | 2018 |
Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypertension | 2018 |
Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvasta | 2017 |
Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvasta | 2017 |
Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvasta | 2017 |
Impact of metformin on serum prostate-specific antigen levels: Data from the national health and nutrition examination survey 2007 to 2008.
Topics: Adult; Diabetes Mellitus; Humans; Logistic Models; Male; Metformin; Middle Aged; Nutrition Surveys; | 2017 |
Impact of metformin on serum prostate-specific antigen levels: Data from the national health and nutrition examination survey 2007 to 2008.
Topics: Adult; Diabetes Mellitus; Humans; Logistic Models; Male; Metformin; Middle Aged; Nutrition Surveys; | 2017 |
Impact of metformin on serum prostate-specific antigen levels: Data from the national health and nutrition examination survey 2007 to 2008.
Topics: Adult; Diabetes Mellitus; Humans; Logistic Models; Male; Metformin; Middle Aged; Nutrition Surveys; | 2017 |
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.
Topics: 3' Untranslated Regions; Aged; Base Sequence; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchyma | 2018 |
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.
Topics: 3' Untranslated Regions; Aged; Base Sequence; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchyma | 2018 |
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.
Topics: 3' Untranslated Regions; Aged; Base Sequence; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchyma | 2018 |
Metformin combined with quercetin synergistically repressed prostate cancer cells via inhibition of VEGF/PI3K/Akt signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Down | 2018 |
Metformin combined with quercetin synergistically repressed prostate cancer cells via inhibition of VEGF/PI3K/Akt signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Down | 2018 |
Metformin combined with quercetin synergistically repressed prostate cancer cells via inhibition of VEGF/PI3K/Akt signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Down | 2018 |
Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cancer Survivors; Databa | 2018 |
Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cancer Survivors; Databa | 2018 |
Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cancer Survivors; Databa | 2018 |
Editorial Comment.
Topics: Androgen Antagonists; Humans; Male; Metformin; Prostatic Neoplasms | 2018 |
Editorial Comment.
Topics: Androgen Antagonists; Humans; Male; Metformin; Prostatic Neoplasms | 2018 |
Editorial Comment.
Topics: Androgen Antagonists; Humans; Male; Metformin; Prostatic Neoplasms | 2018 |
The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.
Topics: Adult; Aged; Black or African American; Body Mass Index; Diabetes Complications; Diabetes Mellitus; | 2018 |
The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.
Topics: Adult; Aged; Black or African American; Body Mass Index; Diabetes Complications; Diabetes Mellitus; | 2018 |
The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.
Topics: Adult; Aged; Black or African American; Body Mass Index; Diabetes Complications; Diabetes Mellitus; | 2018 |
Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database.
Topics: Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Disease-Free Survival; Hu | 2018 |
Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database.
Topics: Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Disease-Free Survival; Hu | 2018 |
Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database.
Topics: Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Disease-Free Survival; Hu | 2018 |
Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.
Topics: Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus; Drug Therapy, Combination; Follow-Up St | 2019 |
Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.
Topics: Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus; Drug Therapy, Combination; Follow-Up St | 2019 |
Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.
Topics: Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus; Drug Therapy, Combination; Follow-Up St | 2019 |
Metformin inhibits prostate cancer growth induced by a high-fat diet in Pten-deficient model mice.
Topics: Animals; Diet, High-Fat; Disease Progression; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Trans | 2019 |
Metformin inhibits prostate cancer growth induced by a high-fat diet in Pten-deficient model mice.
Topics: Animals; Diet, High-Fat; Disease Progression; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Trans | 2019 |
Metformin inhibits prostate cancer growth induced by a high-fat diet in Pten-deficient model mice.
Topics: Animals; Diet, High-Fat; Disease Progression; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Trans | 2019 |
Adiponectin: the "unusual suspect" between insulin resistance and cancer?
Topics: Adiponectin; Humans; Insulin Resistance; Male; Metformin; Prostatic Neoplasms | 2019 |
Adiponectin: the "unusual suspect" between insulin resistance and cancer?
Topics: Adiponectin; Humans; Insulin Resistance; Male; Metformin; Prostatic Neoplasms | 2019 |
Adiponectin: the "unusual suspect" between insulin resistance and cancer?
Topics: Adiponectin; Humans; Insulin Resistance; Male; Metformin; Prostatic Neoplasms | 2019 |
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incide | 2019 |
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incide | 2019 |
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incide | 2019 |
Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Cell Survival; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2019 |
Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Cell Survival; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2019 |
Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Cell Survival; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2019 |
Heme Oxygenase-1 Inhibition Sensitizes Human Prostate Cancer Cells towards Glucose Deprivation and Metformin-Mediated Cell Death.
Topics: Apoptosis; Cell Line, Tumor; Enzyme Inhibitors; Glucose; Heme Oxygenase-1; Humans; Male; Metformin; | 2019 |
Heme Oxygenase-1 Inhibition Sensitizes Human Prostate Cancer Cells towards Glucose Deprivation and Metformin-Mediated Cell Death.
Topics: Apoptosis; Cell Line, Tumor; Enzyme Inhibitors; Glucose; Heme Oxygenase-1; Humans; Male; Metformin; | 2019 |
Heme Oxygenase-1 Inhibition Sensitizes Human Prostate Cancer Cells towards Glucose Deprivation and Metformin-Mediated Cell Death.
Topics: Apoptosis; Cell Line, Tumor; Enzyme Inhibitors; Glucose; Heme Oxygenase-1; Humans; Male; Metformin; | 2019 |
The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
Topics: Adult; Aged; Cohort Studies; Disease Progression; Humans; Insurance, Health; Male; Metformin; Middle | 2019 |
The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
Topics: Adult; Aged; Cohort Studies; Disease Progression; Humans; Insurance, Health; Male; Metformin; Middle | 2019 |
The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
Topics: Adult; Aged; Cohort Studies; Disease Progression; Humans; Insurance, Health; Male; Metformin; Middle | 2019 |
Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Culture Media, Conditioned; Cyto | 2013 |
Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Culture Media, Conditioned; Cyto | 2013 |
Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Culture Media, Conditioned; Cyto | 2013 |
Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant di
Topics: Androgen Antagonists; Humans; Male; Metformin; Orchiectomy; Prostatic Neoplasms | 2013 |
Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant di
Topics: Androgen Antagonists; Humans; Male; Metformin; Orchiectomy; Prostatic Neoplasms | 2013 |
Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant di
Topics: Androgen Antagonists; Humans; Male; Metformin; Orchiectomy; Prostatic Neoplasms | 2013 |
Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
Topics: Androgen Antagonists; Humans; Male; Metformin; Orchiectomy; Prostatic Neoplasms | 2013 |
Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
Topics: Androgen Antagonists; Humans; Male; Metformin; Orchiectomy; Prostatic Neoplasms | 2013 |
Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
Topics: Androgen Antagonists; Humans; Male; Metformin; Orchiectomy; Prostatic Neoplasms | 2013 |
Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Gene Ex | 2013 |
Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Gene Ex | 2013 |
Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Gene Ex | 2013 |
Breast and prostate cancer survivors in a diabetic cohort: results from the Living with Diabetes Study.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cohort Studies; Comorbidity; Cross-Sectional Studies; Dia | 2013 |
Breast and prostate cancer survivors in a diabetic cohort: results from the Living with Diabetes Study.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cohort Studies; Comorbidity; Cross-Sectional Studies; Dia | 2013 |
Breast and prostate cancer survivors in a diabetic cohort: results from the Living with Diabetes Study.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cohort Studies; Comorbidity; Cross-Sectional Studies; Dia | 2013 |
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Citric Acid Cycle; Disease Models, Animal; Glucose; G | 2013 |
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Citric Acid Cycle; Disease Models, Animal; Glucose; G | 2013 |
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Citric Acid Cycle; Disease Models, Animal; Glucose; G | 2013 |
Effect of metformin on prostate cancer outcomes after radical prostatectomy.
Topics: Aged; Follow-Up Studies; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle | 2014 |
Effect of metformin on prostate cancer outcomes after radical prostatectomy.
Topics: Aged; Follow-Up Studies; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle | 2014 |
Effect of metformin on prostate cancer outcomes after radical prostatectomy.
Topics: Aged; Follow-Up Studies; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle | 2014 |
Association between metformin use and risk of prostate cancer and its grade.
Topics: Aged; Aged, 80 and over; Canada; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2 | 2013 |
Association between metformin use and risk of prostate cancer and its grade.
Topics: Aged; Aged, 80 and over; Canada; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2 | 2013 |
Association between metformin use and risk of prostate cancer and its grade.
Topics: Aged; Aged, 80 and over; Canada; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2 | 2013 |
Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Topics: Aged; Cause of Death; Cohort Studies; Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformi | 2013 |
Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Topics: Aged; Cause of Death; Cohort Studies; Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformi | 2013 |
Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Topics: Aged; Cause of Death; Cohort Studies; Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformi | 2013 |
The time is ripe for a randomized trial of metformin in clinically localized prostate cancer.
Topics: Humans; Male; Metformin; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trial | 2013 |
The time is ripe for a randomized trial of metformin in clinically localized prostate cancer.
Topics: Humans; Male; Metformin; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trial | 2013 |
The time is ripe for a randomized trial of metformin in clinically localized prostate cancer.
Topics: Humans; Male; Metformin; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trial | 2013 |
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer.
Topics: Aged; Diabetes Mellitus; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor | 2014 |
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer.
Topics: Aged; Diabetes Mellitus; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor | 2014 |
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer.
Topics: Aged; Diabetes Mellitus; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor | 2014 |
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
Topics: Aged; Databases, Factual; Diabetes Mellitus; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; M | 2013 |
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
Topics: Aged; Databases, Factual; Diabetes Mellitus; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; M | 2013 |
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
Topics: Aged; Databases, Factual; Diabetes Mellitus; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; M | 2013 |
The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells.
Topics: AMP-Activated Protein Kinases; Anilides; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Rela | 2014 |
The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells.
Topics: AMP-Activated Protein Kinases; Anilides; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Rela | 2014 |
The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells.
Topics: AMP-Activated Protein Kinases; Anilides; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Rela | 2014 |
Metformin targets c-MYC oncogene to prevent prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Transfor | 2013 |
Metformin targets c-MYC oncogene to prevent prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Transfor | 2013 |
Metformin targets c-MYC oncogene to prevent prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Transfor | 2013 |
Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response.
Topics: Animals; Cell Hypoxia; Colorectal Neoplasms; Electron Transport Complex I; HCT116 Cells; Humans; Mal | 2013 |
Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response.
Topics: Animals; Cell Hypoxia; Colorectal Neoplasms; Electron Transport Complex I; HCT116 Cells; Humans; Mal | 2013 |
Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response.
Topics: Animals; Cell Hypoxia; Colorectal Neoplasms; Electron Transport Complex I; HCT116 Cells; Humans; Mal | 2013 |
Reply to M.M.J. Zanders et al.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Reply to M.M.J. Zanders et al.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Reply to M.M.J. Zanders et al.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Reply to M.M.J. Zanders et al.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Reply to M.M.J. Zanders et al.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Reply to M.M.J. Zanders et al.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication?
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication?
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication?
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.
Topics: Androgens; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Membrane; CREB-Binding Protein; | 2014 |
Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.
Topics: Androgens; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Membrane; CREB-Binding Protein; | 2014 |
Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.
Topics: Androgens; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Membrane; CREB-Binding Protein; | 2014 |
Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Movement; Down-Regulation; Humans; Male; Metformin; Microtubule Proteins | 2014 |
Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Movement; Down-Regulation; Humans; Male; Metformin; Microtubule Proteins | 2014 |
Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Movement; Down-Regulation; Humans; Male; Metformin; Microtubule Proteins | 2014 |
Repurposing to fight cancer: the metformin-prostate cancer connection.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Diab | 2014 |
Repurposing to fight cancer: the metformin-prostate cancer connection.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Diab | 2014 |
Repurposing to fight cancer: the metformin-prostate cancer connection.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Diab | 2014 |
Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer.
Topics: Cell Proliferation; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Forkhead Transcripti | 2014 |
Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer.
Topics: Cell Proliferation; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Forkhead Transcripti | 2014 |
Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer.
Topics: Cell Proliferation; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Forkhead Transcripti | 2014 |
Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKCS in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; DNA Breaks, Double-Stranded; ErbB Receptors; Histones; Humans; Male; Metf | 2014 |
Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKCS in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; DNA Breaks, Double-Stranded; ErbB Receptors; Histones; Humans; Male; Metf | 2014 |
Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKCS in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; DNA Breaks, Double-Stranded; ErbB Receptors; Histones; Humans; Male; Metf | 2014 |
Metformin use and prostate cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Denmark; Diabetes Mellitus; Drug Prescriptions | 2014 |
Metformin use and prostate cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Denmark; Diabetes Mellitus; Drug Prescriptions | 2014 |
Metformin use and prostate cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Denmark; Diabetes Mellitus; Drug Prescriptions | 2014 |
A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Humans; Male; Metformin; Middle Aged; Neoadj | 2014 |
A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Humans; Male; Metformin; Middle Aged; Neoadj | 2014 |
A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Humans; Male; Metformin; Middle Aged; Neoadj | 2014 |
Metformin to prevent prostate cancer: a call to unite.
Topics: Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Metformin to prevent prostate cancer: a call to unite.
Topics: Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Metformin to prevent prostate cancer: a call to unite.
Topics: Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Prostate cancer: metformin--the new wonder drug?
Topics: Antineoplastic Agents; Evidence-Based Medicine; Humans; Male; Metformin; Prostatic Neoplasms; Treatm | 2014 |
Prostate cancer: metformin--the new wonder drug?
Topics: Antineoplastic Agents; Evidence-Based Medicine; Humans; Male; Metformin; Prostatic Neoplasms; Treatm | 2014 |
Prostate cancer: metformin--the new wonder drug?
Topics: Antineoplastic Agents; Evidence-Based Medicine; Humans; Male; Metformin; Prostatic Neoplasms; Treatm | 2014 |
Re: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Re: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Re: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
The use of metformin in patients with prostate cancer and the risk of death.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; | 2014 |
The use of metformin in patients with prostate cancer and the risk of death.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; | 2014 |
The use of metformin in patients with prostate cancer and the risk of death.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; | 2014 |
Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity.
Topics: Amiodarone; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Drug Resis | 2014 |
Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity.
Topics: Amiodarone; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Drug Resis | 2014 |
Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity.
Topics: Amiodarone; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Drug Resis | 2014 |
Reply from authors re: David Margel. Metformin to prevent prostate cancer: a call to unite. Eur urol 2014;66:1021-2.
Topics: Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Reply from authors re: David Margel. Metformin to prevent prostate cancer: a call to unite. Eur urol 2014;66:1021-2.
Topics: Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Reply from authors re: David Margel. Metformin to prevent prostate cancer: a call to unite. Eur urol 2014;66:1021-2.
Topics: Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Cell Growth Processes; Cell Line, Tumor; HEK293 | 2014 |
SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Cell Growth Processes; Cell Line, Tumor; HEK293 | 2014 |
SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Cell Growth Processes; Cell Line, Tumor; HEK293 | 2014 |
Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inciden | 2014 |
Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inciden | 2014 |
Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inciden | 2014 |
Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4.
Topics: Antigens, CD; beta Catenin; Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Trans | 2014 |
Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4.
Topics: Antigens, CD; beta Catenin; Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Trans | 2014 |
Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4.
Topics: Antigens, CD; beta Catenin; Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Trans | 2014 |
Use of crowdsourcing for cancer clinical trial development.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Crowdsourcing; Feasibility Studies; Humans; Interne | 2014 |
Use of crowdsourcing for cancer clinical trial development.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Crowdsourcing; Feasibility Studies; Humans; Interne | 2014 |
Use of crowdsourcing for cancer clinical trial development.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Crowdsourcing; Feasibility Studies; Humans; Interne | 2014 |
Re: metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Re: metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Re: metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2014 |
Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).
Topics: Aged; Early Detection of Cancer; Humans; Hypoglycemic Agents; Incidence; Kallikreins; Male; Metformi | 2015 |
Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).
Topics: Aged; Early Detection of Cancer; Humans; Hypoglycemic Agents; Incidence; Kallikreins; Male; Metformi | 2015 |
Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).
Topics: Aged; Early Detection of Cancer; Humans; Hypoglycemic Agents; Incidence; Kallikreins; Male; Metformi | 2015 |
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferatio | 2015 |
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferatio | 2015 |
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferatio | 2015 |
Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells.
Topics: Actin Cytoskeleton; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; | 2015 |
Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells.
Topics: Actin Cytoskeleton; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; | 2015 |
Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells.
Topics: Actin Cytoskeleton; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; | 2015 |
Obesity, metformin and prostate cancer risk.
Topics: Humans; Insulin; Male; Metformin; Obesity; Prostatic Neoplasms; Risk Factors | 2014 |
Obesity, metformin and prostate cancer risk.
Topics: Humans; Insulin; Male; Metformin; Obesity; Prostatic Neoplasms; Risk Factors | 2014 |
Obesity, metformin and prostate cancer risk.
Topics: Humans; Insulin; Male; Metformin; Obesity; Prostatic Neoplasms; Risk Factors | 2014 |
The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.
Topics: Aspirin; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents | 2015 |
The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.
Topics: Aspirin; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents | 2015 |
The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.
Topics: Aspirin; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents | 2015 |
Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin.
Topics: Energy Metabolism; Glucose; Humans; Hypoglycemic Agents; Male; Metformin; Polymorphism, Single Nucle | 2015 |
Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin.
Topics: Energy Metabolism; Glucose; Humans; Hypoglycemic Agents; Male; Metformin; Polymorphism, Single Nucle | 2015 |
Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin.
Topics: Energy Metabolism; Glucose; Humans; Hypoglycemic Agents; Male; Metformin; Polymorphism, Single Nucle | 2015 |
Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulati | 2015 |
Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulati | 2015 |
Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulati | 2015 |
Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Topics: Androgen Antagonists; Androgens; Anilides; Apoptosis; Cell Line, Tumor; Cell Survival; Down-Regulati | 2015 |
Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Topics: Androgen Antagonists; Androgens; Anilides; Apoptosis; Cell Line, Tumor; Cell Survival; Down-Regulati | 2015 |
Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Topics: Androgen Antagonists; Androgens; Anilides; Apoptosis; Cell Line, Tumor; Cell Survival; Down-Regulati | 2015 |
Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway.
Topics: AMP-Activated Protein Kinases; Cell Cycle; Cell Line, Tumor; Cholecalciferol; Dose-Response Relation | 2015 |
Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway.
Topics: AMP-Activated Protein Kinases; Cell Cycle; Cell Line, Tumor; Cholecalciferol; Dose-Response Relation | 2015 |
Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway.
Topics: AMP-Activated Protein Kinases; Cell Cycle; Cell Line, Tumor; Cholecalciferol; Dose-Response Relation | 2015 |
Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Pro | 2015 |
Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Pro | 2015 |
Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Pro | 2015 |
Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroi | 2015 |
Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroi | 2015 |
Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroi | 2015 |
Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells.
Topics: Acetyl-CoA Carboxylase; Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Cell Prolif | 2015 |
Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells.
Topics: Acetyl-CoA Carboxylase; Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Cell Prolif | 2015 |
Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells.
Topics: Acetyl-CoA Carboxylase; Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Cell Prolif | 2015 |
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Topics: Adenylate Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line | 2015 |
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Topics: Adenylate Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line | 2015 |
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Topics: Adenylate Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line | 2015 |
No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colorectal Neoplasms; Databases, Factual; Diabetes | 2015 |
No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colorectal Neoplasms; Databases, Factual; Diabetes | 2015 |
No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colorectal Neoplasms; Databases, Factual; Diabetes | 2015 |
Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.
Topics: Active Transport, Cell Nucleus; Animals; Binding Sites; Carcinoma; Carrier Proteins; Cell Line, Tumo | 2015 |
Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.
Topics: Active Transport, Cell Nucleus; Animals; Binding Sites; Carcinoma; Carrier Proteins; Cell Line, Tumo | 2015 |
Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.
Topics: Active Transport, Cell Nucleus; Animals; Binding Sites; Carcinoma; Carrier Proteins; Cell Line, Tumo | 2015 |
Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
Topics: Aged; Databases, Factual; Diabetes Mellitus; Disease-Free Survival; Humans; Hypoglycemic Agents; Ins | 2015 |
Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
Topics: Aged; Databases, Factual; Diabetes Mellitus; Disease-Free Survival; Humans; Hypoglycemic Agents; Ins | 2015 |
Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
Topics: Aged; Databases, Factual; Diabetes Mellitus; Disease-Free Survival; Humans; Hypoglycemic Agents; Ins | 2015 |
Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells.
Topics: AMP-Activated Protein Kinases; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Cadherins; C | 2015 |
Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells.
Topics: AMP-Activated Protein Kinases; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Cadherins; C | 2015 |
Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells.
Topics: AMP-Activated Protein Kinases; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Cadherins; C | 2015 |
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug | 2015 |
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug | 2015 |
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug | 2015 |
Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression.
Topics: Cell Movement; Cell Proliferation; Eye Proteins; Humans; Hypoglycemic Agents; Male; Metformin; Nerve | 2016 |
Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression.
Topics: Cell Movement; Cell Proliferation; Eye Proteins; Humans; Hypoglycemic Agents; Male; Metformin; Nerve | 2016 |
Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression.
Topics: Cell Movement; Cell Proliferation; Eye Proteins; Humans; Hypoglycemic Agents; Male; Metformin; Nerve | 2016 |
Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Health Status Disparities | 2016 |
Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Health Status Disparities | 2016 |
Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Health Status Disparities | 2016 |
Metformin Has a Positive Therapeutic Effect on Prostate Cancer in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Mi | 2016 |
Metformin Has a Positive Therapeutic Effect on Prostate Cancer in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Mi | 2016 |
Metformin Has a Positive Therapeutic Effect on Prostate Cancer in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Mi | 2016 |
Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epigenesis | 2016 |
Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epigenesis | 2016 |
Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epigenesis | 2016 |
Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2016 |
Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2016 |
Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic Neoplasms | 2016 |
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
Topics: Androgen Antagonists; Drug Repositioning; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglyc | 2016 |
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
Topics: Androgen Antagonists; Drug Repositioning; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglyc | 2016 |
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
Topics: Androgen Antagonists; Drug Repositioning; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglyc | 2016 |
Tumor features and survival after radical prostatectomy among antidiabetic drug users.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Mal | 2016 |
Tumor features and survival after radical prostatectomy among antidiabetic drug users.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Mal | 2016 |
Tumor features and survival after radical prostatectomy among antidiabetic drug users.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Mal | 2016 |
Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inc | 2016 |
Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inc | 2016 |
Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inc | 2016 |
Activation of AMP-activated Protein Kinase by Metformin Induces Protein Acetylation in Prostate and Ovarian Cancer Cells.
Topics: Acetyl Coenzyme A; Acetylation; AMP-Activated Protein Kinases; Female; Gene Expression Regulation, N | 2016 |
Activation of AMP-activated Protein Kinase by Metformin Induces Protein Acetylation in Prostate and Ovarian Cancer Cells.
Topics: Acetyl Coenzyme A; Acetylation; AMP-Activated Protein Kinases; Female; Gene Expression Regulation, N | 2016 |
Activation of AMP-activated Protein Kinase by Metformin Induces Protein Acetylation in Prostate and Ovarian Cancer Cells.
Topics: Acetyl Coenzyme A; Acetylation; AMP-Activated Protein Kinases; Female; Gene Expression Regulation, N | 2016 |
Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Dea | 2017 |
Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Dea | 2017 |
Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Dea | 2017 |
Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Male; Metf | 2017 |
Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Male; Metf | 2017 |
Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Male; Metf | 2017 |
Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2017 |
Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2017 |
Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2017 |
Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis.
Topics: Aged; Animals; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2 Inhibitors; Dinoprostone; Epithelia | 2017 |
Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis.
Topics: Aged; Animals; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2 Inhibitors; Dinoprostone; Epithelia | 2017 |
Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis.
Topics: Aged; Animals; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2 Inhibitors; Dinoprostone; Epithelia | 2017 |
Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study.
Topics: Aged; Aged, 80 and over; British Columbia; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Stud | 2017 |
Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study.
Topics: Aged; Aged, 80 and over; British Columbia; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Stud | 2017 |
Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study.
Topics: Aged; Aged, 80 and over; British Columbia; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Stud | 2017 |
Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Disease-Free Survival; Dose-Response Relationship, Drug; Fem | 2017 |
Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Disease-Free Survival; Dose-Response Relationship, Drug; Fem | 2017 |
Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Disease-Free Survival; Dose-Response Relationship, Drug; Fem | 2017 |
Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Topics: Aged; Diabetes Mellitus; Dose-Response Relationship, Drug; Early Detection of Cancer; Finland; Human | 2017 |
Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Topics: Aged; Diabetes Mellitus; Dose-Response Relationship, Drug; Early Detection of Cancer; Finland; Human | 2017 |
Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Topics: Aged; Diabetes Mellitus; Dose-Response Relationship, Drug; Early Detection of Cancer; Finland; Human | 2017 |
The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease | 2017 |
The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease | 2017 |
The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease | 2017 |
Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes.
Topics: Androgen Antagonists; Diabetes Mellitus, Type 2; Humans; Male; Metabolic Syndrome; Metformin; Obesit | 2009 |
Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes.
Topics: Androgen Antagonists; Diabetes Mellitus, Type 2; Humans; Male; Metabolic Syndrome; Metformin; Obesit | 2009 |
Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes.
Topics: Androgen Antagonists; Diabetes Mellitus, Type 2; Humans; Male; Metabolic Syndrome; Metformin; Obesit | 2009 |
The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.
Topics: Adiponectin; AMP-Activated Protein Kinases; Carcinoma; Cell Proliferation; Colonic Neoplasms; Cytost | 2008 |
The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.
Topics: Adiponectin; AMP-Activated Protein Kinases; Carcinoma; Cell Proliferation; Colonic Neoplasms; Cytost | 2008 |
The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.
Topics: Adiponectin; AMP-Activated Protein Kinases; Carcinoma; Cell Proliferation; Colonic Neoplasms; Cytost | 2008 |
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Met | 2009 |
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Met | 2009 |
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Met | 2009 |
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Topics: Adenosine Triphosphate; Adenylate Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2010 |
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Topics: Adenosine Triphosphate; Adenylate Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2010 |
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Topics: Adenosine Triphosphate; Adenylate Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2010 |
The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells.
Topics: AMP-Activated Protein Kinases; Antimetabolites; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; | 2010 |
The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells.
Topics: AMP-Activated Protein Kinases; Antimetabolites; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; | 2010 |
The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells.
Topics: AMP-Activated Protein Kinases; Antimetabolites; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; | 2010 |
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.
Topics: Animals; Diet; Dietary Carbohydrates; Dietary Fats; Gluconeogenesis; Hypoglycemic Agents; Insulin; I | 2010 |
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.
Topics: Animals; Diet; Dietary Carbohydrates; Dietary Fats; Gluconeogenesis; Hypoglycemic Agents; Insulin; I | 2010 |
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.
Topics: Animals; Diet; Dietary Carbohydrates; Dietary Fats; Gluconeogenesis; Hypoglycemic Agents; Insulin; I | 2010 |
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.
Topics: AMP-Activated Protein Kinases; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle | 2010 |
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.
Topics: AMP-Activated Protein Kinases; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle | 2010 |
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.
Topics: AMP-Activated Protein Kinases; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle | 2010 |
Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin.
Topics: Aged; Antineoplastic Agents; Diabetes Mellitus, Type 2; Disease-Free Survival; Humans; Hypoglycemic | 2010 |
Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin.
Topics: Aged; Antineoplastic Agents; Diabetes Mellitus, Type 2; Disease-Free Survival; Humans; Hypoglycemic | 2010 |
Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin.
Topics: Aged; Antineoplastic Agents; Diabetes Mellitus, Type 2; Disease-Free Survival; Humans; Hypoglycemic | 2010 |
Metformin and the incidence of prostate cancer in patients with type 2 diabetes.
Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hy | 2011 |
Metformin and the incidence of prostate cancer in patients with type 2 diabetes.
Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hy | 2011 |
Metformin and the incidence of prostate cancer in patients with type 2 diabetes.
Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hy | 2011 |
Diabetes mellitus type 2 through oncology lens.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Insulin; Isc | 2011 |
Diabetes mellitus type 2 through oncology lens.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Insulin; Isc | 2011 |
Diabetes mellitus type 2 through oncology lens.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Insulin; Isc | 2011 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Car | 2011 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Car | 2011 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Car | 2011 |
Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kaplan-Meier | 2011 |
Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kaplan-Meier | 2011 |
Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kaplan-Meier | 2011 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Che | 2011 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Che | 2011 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Che | 2011 |
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
Topics: AMP-Activated Protein Kinases; Animals; Cell Cycle; Cell Line, Tumor; Cyclin D1; Humans; Male; Metfo | 2011 |
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
Topics: AMP-Activated Protein Kinases; Animals; Cell Cycle; Cell Line, Tumor; Cyclin D1; Humans; Male; Metfo | 2011 |
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
Topics: AMP-Activated Protein Kinases; Animals; Cell Cycle; Cell Line, Tumor; Cyclin D1; Humans; Male; Metfo | 2011 |
Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells.
Topics: Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Human | 2012 |
Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells.
Topics: Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Human | 2012 |
Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells.
Topics: Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Human | 2012 |
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2012 |
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2012 |
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2012 |
Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA R | 2012 |
Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA R | 2012 |
Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA R | 2012 |
Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Survival; Cytoprotection; Drug Synergism; H | 2012 |
Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Survival; Cytoprotection; Drug Synergism; H | 2012 |
Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Survival; Cytoprotection; Drug Synergism; H | 2012 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; | 2013 |
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; | 2013 |
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; | 2013 |
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.
Topics: Aged; Androgen Antagonists; Follow-Up Studies; Humans; Male; Metformin; Middle Aged; Orchiectomy; Pr | 2013 |
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.
Topics: Aged; Androgen Antagonists; Follow-Up Studies; Humans; Male; Metformin; Middle Aged; Orchiectomy; Pr | 2013 |
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.
Topics: Aged; Androgen Antagonists; Follow-Up Studies; Humans; Male; Metformin; Middle Aged; Orchiectomy; Pr | 2013 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferatio | 2008 |
[Reversible lactic acidosis in a diabetic on high dose metformin (author's transl)].
Topics: Adenoma; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Humans; Lactates; Male; M | 1980 |
[Reversible lactic acidosis in a diabetic on high dose metformin (author's transl)].
Topics: Adenoma; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Humans; Lactates; Male; M | 1980 |
[Reversible lactic acidosis in a diabetic on high dose metformin (author's transl)].
Topics: Adenoma; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Humans; Lactates; Male; M | 1980 |
Fibrinolytic activity and haemagglutination inhibition immunoassays.
Topics: Adult; Aged; Biguanides; Clofibrate; Coronary Disease; Ethylestrenol; Female; Fibrin; Fibrinogen; Fi | 1970 |
Fibrinolytic activity and haemagglutination inhibition immunoassays.
Topics: Adult; Aged; Biguanides; Clofibrate; Coronary Disease; Ethylestrenol; Female; Fibrin; Fibrinogen; Fi | 1970 |
Fibrinolytic activity and haemagglutination inhibition immunoassays.
Topics: Adult; Aged; Biguanides; Clofibrate; Coronary Disease; Ethylestrenol; Female; Fibrin; Fibrinogen; Fi | 1970 |